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Abstract 
 
Mosquito-borne viral (arboviral) infections, such as dengue, chikungunya, and Zika, are of 
significant public health importance in the Caribbean. These viruses cause significant morbidity 
in affected communities. Further, arboviral outbreaks can affect economies due to their prevalence 
in the tourist-based economic Caribbean. Currently, these viruses do not have therapeutic 
treatments or licensed vaccines to prevent infection. As such, the best prevention measures involve 
an aspect of integrated vector management, community participation in source reduction of 
mosquito breeding sites and individuals following measures for protection from biting mosquitoes.  
 Mosquito Awareness Week, a yearly program supported by the Pan American Health 
Organization, aims to build community capacity by supporting participating countries in providing 
their communities with education in mosquito control and arboviral diseases prevention methods. 
Building off of the reported activities by participating countries, this paper gives public health 
recommendations for future Mosquito Awareness Week programs as well as general 
recommendations for mosquito control and arboviral diseases prevention in the Caribbean. 
Included in the recommendations are to improve surveillance systems, ensure the incorporation of 
the community in source reduction activities so as to build capacity, developing methods for 
 v 
assessing retention of educational materials, strengthening the healthcare system, and ensuring 
transparent communication. 
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1.0 Background and Early Mosquito Eradication Efforts 
Mosquito-borne diseases, such as dengue, chikungunya, Zika, yellow fever, and malaria 
are all of public health importance to the Americas region. The early 20th century malaria and 
Aedes aegypti eradication programs primarily used larval and adult insecticides, as well as 
quarantining active cases and surveillance of ports, led to the eradication of malaria and yellow 
fever in 1962-1964 in the Caribbean and through most of the Americas region. (Brathwaite, et al., 
2012; Klitting, et al., 2018; Webb, 2016) Due to the successful elimination of the malaria parasite 
and the Yellow Fever virus (YFV), these are less of a concern in the Caribbean, except for  
Hispaniola island, where malaria is still endemic and Haiti still has a poor surveillance system. 
Although, there are instances of imported malaria cases into the non-endemic Caribbean, which is 
a concern due to the already present mosquito vector. (PAHO, 2016c, 2017) For example, Jamaica 
had a malaria outbreak in 2006-2009, the first since 1966, that started from imported cases from 
Haitian refugees. (PAHO, 2016c; WHO, 2017) This highlights the need for robust and vigilant 
surveillance systems.  
Starting in the 1960’s, gains from the successful vector eradication campaigns throughout 
most of the Americas in the early to mid 20th century were quickly lost despite continued efforts 
and commitment from the Pan American Health Organization / World Health Organization 
(PAHO). As countries deemed eradication programs successful, there was a lack of continued 
political will along with the decline in surveillance systems which could not detect small re-
infestations. This led to a slow response to re-infestations. Furthermore, rapidly growing urban 
spaces with a lack of proper and sufficient environmental sanitation and then the evermore 
common domestic and international travel facilitated mosquito re-introduction and spread. 
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Additionally, mosquito resistance to insecticides used in the early 20th century, insufficient 
community participation, and the high cost of materials for eradication and thus less government 
participation to join in with other country’s programs further lead to the decline in early eradication 
program effectiveness. (Brathwaite, et al., 2012)  
Regarding yellow fever, there is an effective and safe vaccine that has been available since 
1951. (Klitting, et al., 2018) Further, the World Health Organization (WHO) recommends a yellow 
fever vaccination coverage of at least 80% to prevent large outbreaks. (WHO, 2019b) Yellow fever 
vaccination rates in Trinidad and Tobago has ranged from 85-96% from 2011-2018. No other 
Caribbean country reported yellow fever vaccination rates. (WHO, 2019d) Trinidad and Tobago 
are the closest islands to mainland South America where Brazil has had a YFV outbreak as recently 
as 2016. Additionally, many of the countries bordering the Caribbean as well as the Caribbean 
island states require yellow fever vaccinations for travelers from endemic areas. (CDC, 2019a; 
Klitting, et al., 2018) The U.S.’s Centers for Disease Control and Prevention (CDC), does not 
recommend a yellow fever vaccination for American travelers to most of the Caribbean region due 
to the low transmission risk. (CDC, 2018)  
Importantly, many Caribbean countries have the mosquito vector for transmitting both 
malaria and yellow fever along with non-human primates susceptible to YFV and thus a concern 
for re-introduction. (Klitting, et al., 2018) Moreover, with climate change facilitating expanding 
locations for already present mosquito vectors, population migration (due to numerous reasons) 
from endemic areas, unplanned urban growth, and water and sanitation problems, all contributes 
to the concern for malaria and yellow fever reintroduction and further highlights the need for strong 
and continued surveillance and proper YFV vaccination coverage. (Paupy, et al., 2009; WHO, 
2017) Along with vector control (VC) methods, prevention methods such as malaria 
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chemoprophylaxis and a safe and effective yellow fever vaccine continue to help protect those in 
the Caribbean. Conversely, there currently are no specific treatments (just supportive treatment of 
symptoms) or medically preventable methods such as vaccines available for dengue, chikungunya, 
or Zika and these arthropod-borne viruses (arboviral diseases) are of significant importance to the 
Caribbean due to their high levels of morbidity. (Brathwaite, et al., 2012; Paupy, et al., 2009; 
Webb, 2016) 
 
Figure 1 Map of the Caribbean. Islands labeled in red indicate independent island countries. 
Source: WorldAtlas 
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1.1 Dengue Virus (DENV) 
Based on clinical and epidemiological descriptions, dengue has been suspected in the 
Americas and specifically the Caribbean (Martinique and Guadeloupe) since 1635, brought by the 
slave trade from Africa. (Brathwaite, et al., 2012; Simmons, et al., 2012). Dengue typically has an 
endemo-epidemic pattern of outbreaks occurring every 3-5 years that has eventually led to an 
endemic status since the 1990s in the Caribbean. Microbiological (and then serological) 
verification of outbreaks did not occur until 1943. (Brathwaite, et al., 2012) There are four distinct 
serotypes of the dengue virus, DENV-1, DENV-2, DENV-3, and DENV-4 and multiple serotypes 
can circulate in a country and during an outbreak. (Brathwaite, et al., 2012; Clapham, et al., 2017; 
Guzman, et al., 2010) The four serotypes share about 65% of their genome, yet they cause nearly 
identical symptomology and similar ecological niches. (Guzman, et al., 2010) By the mid-20th 
century only DENV-2 was circulating in the Americas. With every decade another serotype was 
identified as circulating starting with DENV-3, then DENV-1, and lastly DENV-4 by 1981. 
Additionally, with every decade there was also a noticeable increase in the number of cases (about 
1 million in the 1980s to 4.7 million in the 2000s) and an increase in the number of countries 
affected indicating the resurgence and spread of Aedes mosquitoes. (Brathwaite, et al., 2012)  
In the Americas, humans are the reservoir for the dengue virus, a Flavivirus, which is 
spread by the vector Aedes aegypti and less frequently by the Aedes albopictus mosquito. (Paupy, 
et al., 2009, 2010; Simmons, et al., 2012) These mosquitoes also spread chikungunya, Zika, and 
yellow fever, of which everyone is at risk of varying degree dependent on the region’s rainfall, 
temperature, and environmental sanitation. (Brathwaite, et al., 2012; Tjaden, et al., 2013; Webb, 
2016; WHO, 2019a)  
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Severe dengue was first recognized in the 1950s and remains the leading cause of 
hospitalization and death among children and adults in Latin America. (WHO, 2019a) For travelers 
returning from low- and middle-income countries, malaria followed by dengue are the most 
diagnosed causes for a fever. (WHO, 2019a) After recovering from an infection, there is long-
lived immunity to that serotype but not great protectivity to the other serotypes, thus subsequent 
dengue infections can increase the risk of severe dengue. (Calisher, et al., 1989; Simmons, et al., 
2012) This temporary cross-protection led to the endemo-epidemic pattern. (Clapham, et al., 2017) 
Also, as maternal antibodies can be transferred through the placenta and in breast milk, leading to 
temporary cross-protection in infants. At about 6-12 months of age when the maternal antibodies 
wane in the infant, there is a risk for severe dengue. (Arragain, et al., 2017; Basurko, et al., 2018) 
Severe dengue is thought to be caused by antibody-dependent enhancement (ADE). This is due to 
non-neutralizing antibodies from a previous infection, or for infants the lower concentration of 
maternal antibodies during the infection, facilitating uptake of the virus. (Guzman, et al., 2010; 
Weaver, et al., 2018) Additionally, the severity of subsequent infections in adults increases from 
month-to-month during outbreaks on islands and/or with a longer interval between infections. 
(Guzman, et al., 2010; Simmons, et al., 2012)  
It is estimated that the majority (about 75%) of illnesses are asymptomatic and as such, 
there is probably underreporting and misclassification occurring. (Clapham, et al., 2017; Simmons, 
et al., 2012; Duong, et al., 2015) Further, this leads to silent virus transmission to mosquitoes and 
thus more widespread disease transmission due to asymptomatic individuals being able to keep to 
daily routines compared to symptomatic individuals staying more localized at home or in the 
hospital. (Duong, et al., 2015; Nguyet, et al., 2013) Also, the silent viral transmission and 
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asymptomatic infections can contribute to persistent circulation. Moreover, with insufficient 
surveillance systems there is the possibility of delayed detection of outbreaks. (Duong, et al., 2015)  
With an incubation period of 3-10 days after a bite from an infected mosquito, an estimated 
25% of dengue infected people will have symptoms for 2-7 days ranging from a mild to high-
grade, febrile illness (40°C/104°F) with joint pain and/or severe headache to severe and life 
threatening illness. (Guzman, et al., 2010; Simmons, et al., 2012; Waggoner, et al., 2016; Weaver, 
et al., 2018) An estimated 5% of cases become severe dengue, a hemorrhagic shock which can 
lead to death, and requires proper and prompt medical intervention for 24-48 hours which can 
reduce the number of deaths due to severe dengue from more than 10% to less than 1%. (Guzman, 
et al., 2010; Simmons, et al., 2012) Severe dengue is mainly reported in children and young adults 
due to ADE. (Weaver, et al., 2018) To accomplish the reduction in severe dengue deaths, proper 
case management is necessary and can be obtained through country level capacity building. 
(Guzman, et al., 2010; Weaver, et al., 2018) Further, due to the risk of progressing to severe 
dengue, it is recommended to not take non-steroidal anti-inflammatory drugs (NSAIDs, i.e., aspirin 
and ibuprofen) as they can worsen hemorrhaging. (Simon, et al., 2015) Specific to pregnant 
women, being viremic during pregnancy, more so during late pregnancy and intrapartum, can 
cause maternal-fetal transmission. (Arragain, et al., 2017; Basurko, et al., 2018) Additionally, the 
virus is transmitted through breast milk and through the placenta. (Arragain, et al., 2017; Basurko, 
et al., 2018) Further, neonates can have the same severe symptoms seen in children and adults 
around one week of life for perinatal infected infants. (Arragain, et al., 2017; Basurko, et al., 2018)  
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1.2 Chikungunya virus (CHIKV) 
Based on clinical symptoms described, it is believed that a “dengue” outbreak in 1827 on 
St. Thomas island in the US Virgin Islands, which then spread to the rest of the Caribbean and 
parts of the United States of America (U.S.) and Mexico, was actually the true introduction of 
Chikungunya virus to the Americas. Like for dengue, it is believed CHIKV was brought to the 
Americas via the African slave trade. (Brathwaite, et al., 2012; Yactayo, et al., 2016) As the 1827 
outbreak cannot be proven microbiologically or serologically, what is considered the first 
documented autochthonous case of chikungunya in the Americas occurred on the French side of 
the Caribbean island, St. Martin in December 2013. (PAHO, n.d. e; Yactayo, et al., 2016) At that 
time, St. Martin had a concomitant dengue outbreak and many chikungunya cases were mislabeled 
as dengue as they have similar symptoms. (Yactayo, et al., 2016) Once introduced in St. Martin, 
chikungunya quickly spread throughout the Caribbean. (PAHO, 2016d) As of now, there are no 
nonhuman primate reservoir in the Americas, only in Africa. (ECDC, n.d.; Weaver, et al., 2018) 
As the reemergence of chikungunya in the Americas is so recent, there is a need to determine if 
there are any nonhuman primates and other vertebrates in the Americas that are susceptible and/or 
can become a reservoir. (Weaver, et al., 2018; Yactayo, et al., 2016) If so, Aedes albopictus 
mosquitoes, which are known to transmit the virus can lead to sylvatic and not just urban 
transmission such as with YFV. (CDC, 2018; Weaver, et al., 2016) 
Chikungunya virus is an Alphavirus spread by the vectors Aedes aegypti and Aedes 
albopictus mosquitoes. (Paupy, et al., 2009, 2010; Powers, 2017) CHIKV can also be spread via 
accidental exposure to viremic blood and vertical transmission through intrapartum. (Simon, et al., 
2015) About 3% - 28% of cases are asymptomatic and as such there could be underreporting 
occurring. (Simon, et al., 2015; Weaver, et al., 2018) Those that do have symptomatic illness, 
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typically after a 3-7 day incubation period after being bitten by an infected mosquito, develop a 
sudden high fever (over 39 °C/102 °F) and severe joint pain, followed by a rash over the majority 
of the body. These symptoms can last 7-10 days. (Mehta, et al., 2018; Simon, et al., 2015; 
Waggoner, et al., 2016; Yactayo, et al., 2016) Symptoms of non-severe DENV infections are 
similar to those of chikungunya although the joint pain is more intense and more localized to the 
joints in CHIKV infections. (Weaver, et al., 2018; PAHO, n.d. e) Therefore differential diagnosis 
is critical, as NSAIDs can help alleviate the joint pains from CHIKV but are contraindicated if 
DENV is suspected. (Simon, et al., 2015) Additionally, the arthritis can last for months or years 
and is more apparent in patients over 35 years. (Weaver, et al., 2018) More serious complications 
such as ocular disease, hepatitis, Guillain-Barré syndrome, and myocarditis are rare and if they 
occur, it is typically seen more in the higher risk populations such as those over 65 years of age, 
neonates exposed intrapartum, and those with chronic diseases such as diabetes, heart disease or 
hypertension. (Simon, et al., 2015; Tomashek, et al., 2017; Weaver, et al., 2018; Yactayo, et al., 
2016)  
Guillain- Barré syndrome (GBS) is an autoimmune polyradiculoneuropathy that is 
triggered 2-8 weeks after an infection. GBS is characterized by progressive weakness in the 
extremities, motor dysfunction, paralysis, reduced or absent tendon reflexes, and possibly cranial 
nerve disorders. (Weaver, et al., 2016, 2018; Yuki, et al., 2012) Fatality to CHIKV infections is 
also rare (0-4%) and when it occurs it typically is older adults who are at higher risk. (Weaver, et 
al., 2018) Unique to chikungunya infections, is about 5% - 80% of patients will have a relapse of 
rheumatologic symptoms about 20 months after initial symptoms subsist and can last for months 
or years. (Yactayo, et al., 2016)  
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Interestingly, CHIKV is not neurotropic, but it does infect the meninges and can be found 
in the cerebrospinal fluid. (Weaver, et al., 2018) Specific to pregnant women, the virus does not 
cross the placenta and the highest risk of maternal-fetal transmission (about 50%) is being viremic 
during intrapartum which may cause neonatal complications such as myocardial disease, 
hemorrhaging, acute respiratory failure, and neurological disease, but studies have not found 
CHIKV in breast milk. (Simon, et al., 2015; Weaver, et al., 2018) Of note, there have been a rare 
number of reports of spontaneous abortions following maternal CHIKV infections. (Simon, et al., 
2015; Weaver, et al., 2018; ECDC, n.d.) Once a person recovers from the acute phase they will 
have life-long immunity to chikungunya. (ECDC, n.d.) 
1.3 Zika virus (ZIKV) 
In the Americas region, there was no evidence of Zika prior to 2014. (Weaver, et al., 2016) 
In late 2014, clusters of cases of fever, rash, headache, and muscle and joint pain were noticed in 
Northeastern Brazil which rapidly spread to the entire country by late 2015. (Weaver, et al., 2016) 
The first Caribbean Zika autochthonous case was in Martinique in December of 2015 which then 
spread to other Caribbean countries throughout 2016. (PAHO, 2016b, 2018a) In late 2015, months 
after the outbreak began in Brazil, a higher than usual number of microcephaly in infants in Brazil 
and in French Polynesia lead to the WHO’s declaration of Public Health Emergency of 
International Concern in early 2016. (Weaver, et al., 2016; PAHO, 2016b) Also in early 2016, the 
United States of America reported the first confirmed case of sexually transmitted ZIKV. (PAHO, 
2016b) Although, sexual transmission of ZIKV was first implicated in 2008 when scientists 
returning home from their research site in Senegal, known to be endemic for ZIKV, became sick 
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and spread to his wife but not his children, thus ruling out direct contact as a transmission route. 
(Foy, et al., 2011) 
An experimental study in 1952 showed ZIKV to be neurotropic in mice. (Kindhauser, et 
al., 2016) Yet the mild, self-limiting infections in Africa and Asia may be due to the endemic 
nature, where the infections and thus immunity occurs prior to child-bearing age. As such 
microcephaly and GBS are not seen or they have such a low incidence it’s cause was unrecognized. 
(Weaver, et al., 2016) Additionally, ZIKV infections in Africa and Asia were rare and benign with 
no deaths, hospitalizations, hemorrhagic complications, or neurologic complications and 
seroprevalence studies determined widespread human exposure. (Kindhauser, et al., 2016) 
Conversely, in a naïve population, such as on Yap Island in 2007 and the Americas region in 2015, 
there is a lack of population immunity leading to more cases of microcephaly and GBS. 
(Kindhauser, et al., 2016; Weaver, et al., 2016) 
Accurate Zika virus data in the Americas is not available from early in the outbreak as Zika 
was not a mandatory reported infection. Thus, much of the knowledge today regarding the 
association of microcephaly and GBS to ZIKV was determined with numerous retrospective 
studies. (PAHO, 2016b; de Oliveira, et al., 2017; Weaver, et al., 2016; WHO,  2018a) Additionally, 
the naïve monkeys in the Americas and the lack of monkeys on Yap Island indicates the start of 
those outbreaks are most likely due to mosquitoes. (Gregory, et al., 2017; Kindhauser, et al., 2016; 
Weaver, et al., 2016) Further, due to the enzootic nature of Zika in Africa, there is a need for strong 
surveillance as well as more research to determine if New World nonhuman primates can act as a 
reservoir. If so, Aedes albopictus mosquitoes, which are known to transmit the virus can lead to 
sylvatic and not just urban transmission such as with YFV. (CDC, 2018; Weaver, et al., 2016) 
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Zika virus is a Flavivirus spread by Aedes aegypti and Aedes albopictus mosquitoes, as 
well as through perinatal, sexual, and transplacental transmission (breastfeeding has not been 
established as a source of transmission). (Gregory, et al., 2017; Foy, et al., 2011) About 50%-80% 
of all cases are asymptomatic and thus there may be underdiagnosis. Symptomatic cases are 
typically mild, self-limited illness such as fever, rash, conjunctivitis, and joint pain and thus it is 
easy for ZIKV to be misdiagnosed. (Grossi-Soyster, et al., 2017; Mehta, et al., 2018) Zika has an 
incubation period of 3-14 days and symptoms typically last 2-7 days. (Grossi-Soyster, et al., 2017; 
WHO, 2018b) The main concern with maternal ZIKV infections, regardless of if symptomatic or 
not, is microcephaly and other congenital malformations (congenital Zika syndrome[CZS]) in 
infants as well as the possibility of preterm birth, miscarriage, and intra-uterine growth restriction. 
(Krow-Lucal, et al., 2018; Weaver, et al., 2018; WHO, 2018b) CZS includes other malformations 
such as eye and vision abnormalities, hearing loss, learning disabilities, epilepsy, and cerebral 
palsy. There is greater fetal susceptibility to CZS for infections occurring in the first trimester. 
(Satterfield-Nash, et al., 2017; Weaver, et al., 2018; WHO, 2018a, 2018b) Microcephaly is a 
smaller head size than normal due to abnormal brain development or loss of brain tissue, which 
leads to varying child outcomes according to the extent of brain damage. (WHO, 2018b) Some 
infants with microcephaly develop normally and some infants without microcephaly develop 
congenital Zika syndrome. (WHO,  2018a) The risk of congenital malformations is estimated at 5 
-30% of infants born to women with symptomatic and asymptomatic ZIKV infection during 
pregnancy compared to the normal rate of microcephaly being about one in a thousand infants. 
(Krow-Lucal, et al., 2018; Weaver, et al., 2018; WHO,  2018a, 2018b) Adults can also have long-
term neural effects due to ZIKV infections, including learning and memory impairment. (Weaver, 
et al., 2018) 
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Another concern for adults and children is the development of GBS, neuropathy, and 
myelitis, although those with Zika-induced GBS typically fully recover. (Weaver, et al., 2016, 
2018; WHO, 2018b) GBS can occur due to direct ZIKV infection thus having a short period of 
time between rash and GBS or GBS can occur due to autoimmune cross-reactive antibodies thus 
occurring later after the infection. (Weaver, et al., 2018) Currently, there is only supportive 
treatment, thus the importance of ruling out dengue before giving NSIADs for joint pain. (Simon, 
et al., 2015) For microcephalic infants, early intervention with stimulation may positively impact 
development and there is a need for family counseling and support. (WHO,  2018a) To 
conclusively determine if there is lifelong protective immunity, researchers will need to collect 
data from endemic countries. (Kindhauser, et al., 2016) Based on the lack of microcephaly and 
GBS seen in endemic areas, it is possible that once infected with Zika, there is protective immunity. 
(Weaver, et al., 2016) 
1.4 Vaccines 
Vaccines are currently being researched, developed, and tested in preclinical and clinical 
trials. Until there are safe and approved arboviral vaccines for use in the Caribbean, the current 
best prevention methods involve vector control (outlined below). (WHO, 2018b)  
It is important to have clearly defined clinical endpoints for determining efficacy due to 
the concern for dengue and zika vaccines for the potential for ADE. There is not enough evidence 
to yet determine if antibody cross-reaction in Flaviviruses can cause ADE between dengue and 
Zika. (Barouch, et al., 2017; Dejnirattisai, et al., 2016) Specifically for Zika it will be important to 
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determine efficacy and effectiveness based on CZS and GBS prevention as well as determining 
safe immunization scheduling for women who are or plan to be pregnant. 
Recently, the National Institutes of Health (NIH) published results from a phase I trial 
using a mosquito saliva peptide-based vaccine. The premise was based on previous research 
indicating mosquito saliva has immune modulating proteins. (Pingen, et al., 2016; Vogt, et al., 
2018) Eligible participants were inoculated with two doses and then later exposed to feeding by 
uninfected Aedes aegypti mosquitoes. The vaccine contained four synthetic salivary peptides from 
Anopheles gambiae mosquitoes. After the mosquito feeding, the site was evaluated for redness and 
swelling. There was some mild to moderate vaccine-related adverse events at the injection site and 
seem more in the adjuvant group than the non-adjuvant and control groups. One adjuvant 
participant developed an erythema after the first injection. After feeding, the mosquitoes were 
evaluated for any changes in the life span and progeny survival over the life span (eggs, larvae, 
pupae, and adults) of which there was no difference among vaccine groups. Outcomes were 
promising, the vaccine was considered safe and for the adjuvant group there was a significant 
increase in vaccine-specific antibodies, but all groups had the same antibody levels by the end of 
the study, about one year. The vaccine was proven to be tolerated and immunogenic when 
adjuvanted, thus a viable option for a vector-targeted vaccine. (Manning, et al., 2020) There is 
more research needed to understand the human immune response to mosquito saliva as well as if 
truly protective against each mosquito-borne pathogen. Additionally, there needs to be an 
evaluation of if the vaccines need to be specific to mosquito genus or if there is cross-protection. 
If successful in further clinical trials, this vaccine would eliminate the need for pathogen specific 
vaccines. 
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1.4.1  Dengue vaccines 
In 2015, Sanofi Pasteur’s recombinant tetravalent dengue vaccine with a yellow fever 
backbone (CYD-TDV), Dengvaxia, was licensed for use in a few endemic countries. Of which 
non are Caribbean countries, but the European and U.S. territories can use the vaccine due to 
licensing approval in the United States and in Europe. (FDA, 2019; Sanofi, 2017, 2019) This 
vaccine replaced the RNA for the pre-membrane (PrM) and envelope (E) protein from the yellow 
fever virus vaccine (YF17D) with the corresponding RNA from the four dengue serotypes. (Guy, 
et al., 2010) Data from the vaccine’s clinical trials, phase III/IV, indicated those over nine years 
old had greater efficacy, with vaccine immunity lasting four years. (Guy, et al., 2017; Hadinegoro, 
et al., 2015) Yet an individual’s age, serostatus, and serotype affected vaccine effectiveness and 
those in the placebo group had higher hospitalization rates three years post inoculation. (Guy, et 
al., 2017; Sridhar, et al., 2018) More clinical trials showed the vaccine was ineffective against the 
DENV-2 serotype with re-immunization more effective than first-time. (Capeding, et al., 2014; 
Hadinegoro, et al., 2015; Sabchareon, et al., 2012) 
Due to this information, the WHO made safety recommendations for determining who 
should receive the vaccine via either pre-vaccination screening of individuals, the preferred 
method, or by using recent high resolution documentation of seroprevalence rates of over 80% by 
age 9 years old. This is to ensure those vaccinated have previously been exposed to dengue 
naturally in order to reduce the risk of developing severe dengue. Thus, the vaccine is safe and 
effective for those aged 9 to 45 years who live in dengue endemic areas and have a documented 
exposure to dengue. In higher dengue transmission countries the acceptable age for vaccination 
may be lowered and for lower dengue transmission countries the lower limit of acceptable age may 
be higher. (WHO, 2019e) Recently, the United States Food and Drug Administration (FDA) has 
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approved the vaccine of those aged 9 to 16 years, live in endemic areas, and have a laboratory 
confirmed previous dengue infection. (FDA, 2020) 
Which method to use for Dengvaxia vaccine implementation involves evaluating the 
balance between population level benefits versus individual risk. To determine the optimal age 
range for each country involves knowing at what age is severe dengue incidence the highest by 
using routine hospital laboratory-confirmed surveillance data. Thus the great importance of strong 
surveillance systems and highly specific and sensitive biological tests, such as plaque reduction 
neutralization test (PRNT), IgG antibody detection, or other laboratory confirmed methods used 
for diagnosis and screening. Further, the vaccine should not be considered a tool for outbreak 
response. (Ariën, et al., 2018; CDC, 2017b; WHO, 2019a, 2019e) Even if vaccination becomes 
universally available, it will be important to continue with integrated vector management (IVM), 
described below. Additionally, regardless of vaccination status, those with dengue symptoms 
should seek medical care. Also, those vaccinated should be observed long-term to ensure the 
absence of developing severe dengue disease. (Guzman, et al., 2010)  
A live, attenuated tetravalent dengue vaccine candidate uses DENV-2 as the backbone, 
including the NS-1 or non-structural genome, and incorporates the PrM and E protein RNA from 
DENV-1, 3, and 4, also called TDV or DENVax. This vaccine, developed by Takeda, proved safe 
and efficacious in both phase I trials, testing doses and administration routes, although one 
participant had mild dengue-like symptoms. (Osorio, et al., 2014; George, et al., 2015) Phase II 
trials enrolled adults and children. There were no serious adverse events in both baseline 
seropositive and seronegative participants. (Sirivichayakul, et al., 2016) This vaccine is currently 
in phase III trials. There are other phase I and II trials occurring that are testing dosing regimen, 
including testing a booster dose. (Osorio, et al., 2015) 
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A monovalent vaccine rDENx∆30, where x is the different serotypes, and its derivatives 
are either no longer being pursued or are used as a research tool to develop components to be used 
in a quadrivalent live, attenuated vaccine. This vaccine and its components, including 
TV003/TV005, were developed by NIAID. (WHO, n.d. c) The TV003/TV005 vaccine is a mixture 
of four attenuated recombinant derivatives from the rDENx∆30 research vaccine. The 
TV003/TV005 vaccine had more resistance to DENV-2 than Dengvaxia and thus produced more 
balanced immune responses. Clinical trial participants reported a mild rash and there was 
protection from all serotypes. Yet, more participants produced protective antibodies to TV005, 
which contains more DENV-2 components, than TV003. (Kirkpatrick, et al., 2015, 2016)  
Other dengue vaccine types include live attenuated, inactivated whole cell, recombinant 
subunit, and DNA candidates and are summarized by Deng, et al. (2020) but will be briefly 
mentioned here. Developed by WRAID, the tetravalent live, attenuated vaccines, PIV and LAV, 
used structural protein components. There was promising results in animal studies and there is now 
recruitment for phase I trials. (Deng, et al., 2020; Simmons, et al., 2010) The recombinant subunit 
vaccine, DEN1-80E, uses a recombinant truncated E protein. From phase I trials, the vaccine 
proved safe and efficacious, but without long-lived immunity. (Manoff, et al., 2015) Lastly, the 
DNA vaccine, developed by the US Naval Medical Research Center, started as a monovalent 
plasmid containing PrM and E proteins from DENV-1, but later became tetravalent by combining 
the remaining three serotypes’ monovalent vaccines. In phase I trials, there was low levels of 
protective immunity developed and so further research is evaluating using an adjuvant. (Beckett, 
et al., 2010; Porter, et al., 2012) 
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1.4.2  Chikungunya vaccines 
Chikungunya vaccine development has a long history starting in the 1960s. The early 
efforts involved inactivated African strains, yet they never progressed further than testing in mice 
and monkeys. (Kitaoka, 1967; Powers, 2017) The next vaccine developed was a live, attenuated 
vaccine candidate by Walter Reed Army Institute of Research (WRAID). It was tested in both 
monkeys and mice with promising results. (Harrison, et al., 1967) This vaccine completed phase I 
and II trials before funding as well as the unpredictable chikungunya epidemiology ended the 
vaccine trial in 1998. (McClain, et al., 1998, Edelman, et al., 2000; Hoke, et al., 2012) The phase 
I and II trial results were promising yet some participants experienced arthralgia, a concern given 
this is a common symptom of infection. (McClain, et al., 1998, Edelman, et al., 2000) The 
investigational new drug (IND) protocol for the live, attenuated vaccine was left open until 2011 
for continued research result submissions. Interestingly, after the 2006 chikungunya outbreak in 
La Reunion, this vaccine was requested for additional research purposes by France’s Ministry of 
Health. (Hoke, et al., 2012; Powers, 2017) 
Other chikungunya vaccines were developed after the reemergence and expansion across 
the globe. One promising vaccine in development uses virus-like particles (VLP); these 
structurally look like the CHIKV but it does not contain nucleic acid, and so it is replication 
incompetent. Researchers started with a West African and Central/East African strain and 
discovered there was increased production West African VLP’s from their cell culture. They 
justified continuing with this strain as there is high similarity of amino acids among CHIKV strains 
along with cross-reactive serology thus a vaccine using one strain would be cross protective. 
(Akahata, et al., 2010; Goo, et al., 2016; Powers, et al., 2000) The VLP vaccine was tested in mice 
and monkeys with promising results leading to phase I clinical trials and now phase II trials. 
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(Akahata, et al., 2010; Chang, et al., 2014; Powers, 2017; Weaver, et al., 2018) The vaccine 
produced neutralizing antibodies without negative side effects, yet there was a waning of the 
antibody titer over time. (Chang, et al., 2014; Powers, 2017) 
The other promising CHIKV vaccine is the recombinant, live attenuated measles vaccine 
with CHIKV structural protein genes which then produces a chikungunya VLP. The vaccine has 
been previously used for developing immunity against Flaviviruses in mice and monkeys. 
(Desprès, et al., 2005; Brandler, et al., 2010) This vaccine proved promising in animal studies, but 
during phase I clinical trials there was dose dependent level of protective antibodies developed as 
well as dose dependent severe adverse events such as headaches, musculoskeletal pain, and flu-
like illness. (Brandler, et al., 2013; Ramsauer, et al., 2015) But importantly, there were no 
developments of arthralgia. (Ramsauer, et al., 2015) The vaccine is now in phase II clinical trials.  
Some other vaccines being developed include subunits, live attenuated, DNA, and 
recombinant. None of the other vaccines have gone past the preclinical trials. The article by Powers 
(2017) has a summary of all the current CHIKV vaccines in development. Important for all the 
safety evaluations during clinical trials is the absence of participants developing GBS and 
arthralgia. 
1.4.3  Zika vaccines 
Zika vaccine development is much newer, initiated due to its New World outbreak. 
(Weaver, et al., 2018) There are numerous vaccine candidates in phase I and two are starting phase 
II trials. There are different methods employed such as DNA, inactivated whole cell, mRNA, and 
recombinant vaccines being tested. (WHO, n.d. c) In preclinical trials, all vaccine candidates 
developed neutralizing antibodies in mice as summarized by Abbink, et al. (2017)  
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There are a couple DNA vaccines, of which one is recruiting for Phase II trials. (WHO, 
n.d. c) The DNA vaccines have expressed ZIKV precursor membrane and envelope proteins and 
the National Institute of Allergy and Infectious Diseases (NIAID) has added Japanese encephalitis 
virus envelope stem and for another vaccine they used wild-type ZIKV, currently in phase II trials 
in the Americas and Caribbean. (Tebas, et al., 2017; Gaudinski, et al., 2018) Tested in these phase 
I trials were dosing, immunization schedules, and administration routes of which there was dose-
dependent antibody responses. Importantly, the vaccines were well tolerated with only mild to 
moderate vaccine-associated adverse reactions. 
WRAID has completed phase I trials for three purified, inactivated vaccines. Tested was 
one dose regimen and administration route. There was mild to moderate vaccine related adverse 
effects with neutralizing antibodies produced. They intend to perform follow-up analysis on dosing 
and immunization schedules. (Modjarrad, , et al., 2018) 
The other vaccine type that is in phase I/II trials is mRNA based, developed by Moderna 
Therapeutics. Preclinically, this vaccine and a live-attenuated vaccine were also tested in 
immunocompromised pregnancy mice models. Both vaccines prevented fetal death, yet ZIKV 
RNA was found in various tissues in the mice including the placenta and fetal heads. (Richner, et 
al., 2017) It would be important to study the effects in immunocompetent mice to determine if 
viral replication will also occur.  
As with all of the vaccines that continue to phase III/IV, it will be important to determine 
what is considered an adverse event, such as CZS, and thus it will be important how vaccine 
efficacy will be defined. Additionally, it will be important to ensure safety in all phases of clinical 
trials with the absence of participants developing GBS. Further, it will also be important to 
determine immunization scheduling for pregnant or planning to be pregnant women. The mRNA 
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vaccine would be safer for women of childbearing age due to its lack of viral replication. Whereas 
the live, attenuated vaccine may produce longer-term protection and be used for males and females 
prior to sexual debut but would require adequate time between vaccination and pregnancy. 
(Barouch, et al., 2017; Richner, et al., 2017) It also will be difficult to accomplish phase III trials 
due to the reduction in Zika transmissions globally and there is ethical concerns regarding 
challenging in clinical trials. (Abbink, et al., 2017; NIH, 2017) One way around this is following 
the FDA’s Animal Efficacy Rule by showing strong correlation of protection, ZIKV neutralizing 
antibody titers, in preclinical models that translate to humans when it is unethical to test efficacy 
in humans. (FDA, 2015) Another study design for determining vaccine efficacy is ring vaccination 
as used during the Ebola vaccination trials. (Henao-Restrepo, et al., 2015) If clinical trials continue, 
instead of using the FDA’s Animal Efficacy Rule, there will need to be large trials to accomplish 
enough statistical power due to the rare rates of microcephaly. Moreover, there is also the approach 
of receiving regulatory approval by using clinical endpoints that do not contain CZS. (Barouch, et 
al., 2017) 
1.5 Commonalities of Arboviral Diseases 
Dengue, chikungunya, and Zika infections all have common symptomatology leading to a 
greater difficulty in differential diagnosis. Further, these viruses are spread by the same mosquitoes 
and so have a common geographical distribution. (Paupy, et al., 2009; Waggoner, et al., 2016; 
Weaver, et al., 2018; CDC, 2017c) As such, a differential diagnosis is important as the supportive 
therapy can be different, specifically to not use NSAIDs with a dengue infection. (Simon, et al., 
2015) But differential diagnosis requires biological methods and can be difficult as antibodies to 
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Flaviviruses all cross-react. This cross-reaction can be further complicated by vaccination to other 
Flaviviruses such as yellow fever and Japanese encephalitis leading to a false-positive result. 
(Felix, et al., 2017) Thus the need for more specific diagnostic methods such as multiplex RT-PCR 
to detect mono-infections and co-infections, PRNT, IgG enzyme-linked immunosorbent assay 
(ELISA), as well as other specific biomarkers of infection. (Ariën, et al., 2018; CDC, 2017c; 
Guzman, et al., 2010; Kindhauser, et al., 2016; Waggoner, et al., 2016;) Additionally, dengue 
diagnosis tests have different sensitivity dependent on illness duration. (Simmons, et al., 2012) 
Chikungunya, being an Alphavirus, does not have cross-reactive antibodies to Flaviviruses. (Kam, 
et al., 2015) Further complications include the lack of specific treatments available as there is only 
the option of supportive therapy, including for GBS, microcephaly, and severe dengue. (Guzman, 
et al., 2010; Simon, et al., 2015; Weaver, et al., 2018) There is research into specific treatments 
including anti-CHIKV antibodies given to exposed neonates to prevent vertical transmission 
during intrapartum, evaluating drugs to prevent Flavivirus replication, such as ivermectin which 
is in a phase II/III trial, and antibiotics that prevent ZIKV replication and the negative side effects 
ZIKV has on neural cells. (Barrows, et al., 2016; Couderc, et al., 2009; Mastrangelo, et al., 2012; 
Retallack, et al., 2016) 
Due to the common vector, mosquitoes, it is important to prevent further spread by 
protecting patients from being bitten by mosquitoes in the first week of illness. (Simon, et al., 
2015; PAHO, 2016a) The use of bed nets or screens on windows and doors, use of bugspray, and 
wearing long sleeves and pants can help prevent the spread of infection from sick individuals. 
(Paupy, et al., 2009; Simon, et al., 2015; PAHO, 2016a; WHO, 2019a) Additionally, due to the 
potential for severe symptoms with arboviral diseases, it is recommended by the WHO and the 
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CDC to seek care at a healthcare facility where supportive therapy can lessen disease severity and 
drastically reduce the chance of death to severe dengue. (CDC, 2017b; PAHO, n.d. e) 
1.5.1  Arboviral Diseases’ Impact on Populations 
According to the WHO, dengue’s numerous serotypes and endemo-epidemic pattern of 
outbreaks has an alarming impact on human health, as well as the national and global economies. 
(WHO, 2019a) The chikungunya outbreak is estimated to have cost Venezuelans over 1 billion 
dollars in lost wages. (Yactayo, et al., 2016) For comparison, in 2018 Venezuela had 295 cases 
and the Eastern Caribbean Countries (ECC) region had 144 cases and in 2019 Venezuela has 
reported 52 cases and ECC reported 27 cases. (PAHO, n.d. f) After the ZIKV outbreak in Brazil, 
CZS has had negative socioeconomic consequences for affected families as the mothers take off 
time from work to devote more time caring for their children. (Weaver, et al., 2016) While malaria 
is not a concern for the ECC region and not a large concern for the Caribbean it can be an example 
of economically what is at risk in mosquito-borne disease high-transmission rate areas. Africa is a 
malaria high-transmission rate area and it has been estimated that a 1.3% reduction in Gross 
Domestic Product (GDP) is attributed to malaria. This annual loss is compounded over the years 
with noticeable differences in GDP between countries with and without malaria. Furthermore, in 
high malaria burden countries malaria accounts for up to 40% of public health expenditures, 
between 30% to 50% of the inpatient hospital admissions, and up to 60% of outpatient health clinic 
visits. Moreover, malaria disproportionately affects those who are poor and cannot afford 
treatment and/or have limited access to health care. Clearly, malaria infections trap families and 
communities in poverty. (PAHO, n.d. h) 
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Another impact arboviral diseases have on communities is reduced tourism. The CDC 
issued travel warnings during the Zika outbreak and other outbreaks as well, including the Jamaica 
dengue outbreak in early 2019. (CDC, 2019b)  In 2019, tourism accounted for 15.5% of the total 
economy and 2.4 million jobs in the Caribbean. (World Travel and Tourism Council, 2019) For 
countries where the economy relies on tourism, an outbreak not only hurts those directly affected 
by the disease, but everyone via the country’s economy and individual’s livelihoods. 
The great direct and indirect harm caused by arboviral diseases indicates the importance of 
protecting oneself and the community from arboviral infections. The best method is vaccination, 
yet with none licensed, or for Dengavaxia not currently in use, the next best option is vector control 
and preventing those who are sick from getting bitten by mosquitoes. 
1.6 Information on Aedes mosquitoes 
Aedes mosquitoes are an anthropophilic vector where female Aedes mosquitoes typically 
bite multiple people each feeding period. (Scott, et al., 2000; WHO, 2019a; Klitting, et al., 2018; 
Paupy, et al., 2009) Ae. albopictus is an opportunistic zoophilic feeder, but prefers humans when 
in urban settings, thus an important concern for zoonotic diseases and sylvatic transmissions. 
(Delatte, et al., 2010; Paupy, et al., 2009; Scott, et al., 2000) Aedes mosquitoes usually bite during 
the day and are exophagic, preferential feeding during the early morning and late evening and both 
indoors and outdoors near buildings. (Paupy, et al., 2009; CDC, 2017a; WHO, n.d. a) Additionally, 
Aedes mosquitoes prefer to lay their eggs indoors and in domestic water sources such as discarded 
water bottles and flowerpots above the waterline. Whereas Ae. albopictus is more likely to lay 
eggs in more natural items in peri-urban areas and shady parks such as coconut husks, bamboo 
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stumps, and discarded tires as well as in natural water habitats with plants. (ECDC, 2016a, 2016b; 
PAHO, n.d. e; WHO, n.d. a; Hawley, 1988; Klitting, et al., 2018; Paupy, et al., 2009; Ngoagouni, 
et al., 2015; Powell, et al., 2013) Importantly, Aedes mosquito eggs attach to the containers where 
they are deposited and can survive desiccation for over a year. (Powell, et al., 2013; PAHO, 2016a; 
ECDC, 2016b, WHO, 2019a) The domestic form of Aedes mosquitoes is often found within 100 
meters of human habitats and regardless of if they are the domestic form or not, they have a flight 
range of 25 to 400 meters. (ECDC, 2016a; PAHO, 2016a) Being adapted to the urban environment, 
Aedes mosquitoes do not rely on rainfall for breeding sites. (ECDC, 2016a; Klitting, et al., 2018, 
Paupy, et al., 2009) Interestingly, both Aedes species are capable of coexistence in larval and adult 
habitats and they can coexist with other mosquito genus’. As such, it cannot be assumed that one 
species will displace the other even with Ae. albopictus demonstrating in field studies to have a 
higher population growth rate. (Juliano, et al., 2004; Paupy, et al., 2009; Ngoagouni, et al., 2015)  
Aedes aegypti are confined to the tropics and subtropics region of the world, where as 
Aedes albopictus can also live in temperate and cold temperate regions. (Paupy, et al., 2009; 
Simmons, et al., 2012; WHO, n.d. a) Interestingly, Ae. albopictus is highly adaptive due to their 
tolerances to low temperature (about 9 °C/ 48 °F), ability to hibernate, and the ability to shelter in 
microhabitats which allows for the spread to colder temperate regions. (Paupy, et al., 2009; WHO, 
2019a) Further, Ae. albopictus eggs can suspend development (diapause) overwinter (as long as it 
is less than six months) with temperate mosquitoes’ eggs survive temperatures as low as -10°C/14 
°F and tropical mosquitoes’ eggs survive temperatures as low as -2 °C/ 28 °F. (Paupy, et al., 2009; 
ECDC, 2016b) In shared larval water sources, Ae. aegypti are dominant in early rainy season and 
Ae. albopictus comprise the majority of larvae in late rainy season. (Ngoagouni, et al., 2015; 
Powell, et al., 2013) Most mosquito-borne disease outbreaks occur during and soon after the rainy 
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season as well as at the end of the dry season, although having water containers in and near homes 
can contribute to longer outbreaks that do not end in the dry season. (CDC, 2017a; WHO, n.d. a) 
All these attributes, specifically the anthropophilic and endophilic preferences, indicate urban 
areas are typically more at risk of outbreaks than rural.  
 26 
2.0 Epidemiology 
The Caribbean Mosquito Awareness Week targets the participation of all the Caribbean 
islands. However, the epidemiological data for dengue, chikungunya, and Zika as well as the 
Mosquito Awareness Week 2019 Activities in this report will focus on the countries under the 
PAHO Barbados and ECC office excluding the French Department of the Americas (i.e., French 
Guiana, Guadeloupe, and Martinique). The French Department of the Americas (FD) is excluded 
due to the language barrier and according to PAHO’s Barbados and the ECC office’s Advisor for 
Climate Change and Environmental Determinants of Health, who oversees MAW implementation 
and evaluation, it is difficult to coordinate with these countries due to the fact that overseas 
territories are still under the governance of their mainland country, in this case France. The 
included countries in this evaluation are: Anguilla, Antigua and Barbuda, Barbados, British Virgin 
Islands, the Commonwealth of Dominica, Grenada, Montserrat, Saint Kitts and Nevis, Saint Lucia, 
and Saint Vincent and the Grenadines.  
The epidemiological data for the number of cases of dengue, chikungunya, and Zika came 
from PAHO’s Health Information Platform for the Americas (PLISA) database accessed on July 
16, 2019, as such the epidemiological (epi) week reported in 2019 will be listed in this report. The 
data in PLISA is reported by the country’s Health Ministries to PAHO. (PAHO, n.d. f) The 
chikungunya data for 2015 - 2017 was not listed in PLISA, but came from PAHO’s Chikungunya: 
Data, Maps, and statistics website. (PAHO, n.d. d) All data represented in the figures is the total 
number of cases, i.e., suspected, confirmed, and imported. 
In 2001, PAHO’s 43rd Directing Council developed a framework for dengue prevention 
and control, discussed below. Outlined in this document was recommendations for what to include 
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in dengue case reporting (probable cases, laboratory-confirmed cases, serotypes, deaths, etc.). 
Additionally outlined is the frequency of reporting the data weekly to PAHO, from Ministries of 
Health (MoH), so that PAHO can give the data monthly to the member states. Standardizing the 
necessary information as well as regularly communicating and disseminating the information 
allows for a timelier reaction to any outbreaks for all countries in the Americas region. (PAHO, 
2001) In 2016, PAHO’s 55th Directing Council developed a framework for arboviral prevention 
and control that included strengthening surveillance for Zika and chikungunya. In the resolution 
document, there was no mention of what information to report nor the frequency. (PAHO, 2016d) 
This may explain the low number of reporting countries regarding confirmed cases and deaths 
attributed to chikungunya and Zika compared to dengue. 
 Figure 2 shows the reported dengue cases in Barbados and the ECC excluding FD for 2014 
- 2019. For 2019, there was a range of epi week 6 - 24 being reported and all countries reported 
data for 2019. There was one reported death in Barbados in 2015 and since then there have been 
zero reported deaths from all in the Barbados and ECC region, although Anguilla did not submit a 
report for deaths in 2017. The case fatality rate for the reported deaths is less than 1% which is in 
line with the WHO’s assessment of what proper case management can accomplish. Numerous 
countries saw a spike in dengue cases in 2016. This may be due to the Zika outbreak as it was 
originally difficult to differentiate the two viruses and so some cases may actually be Zika. Another 
possibility is a concomitant dengue outbreak with Zika or even an increased number of patients 
seeking medical care due to the Zika outbreak. The last possible explanation is an increase in cases 
due to lax VC operations contributing to increased mosquito populations. Antigua and Barbuda 
saw a spike in cases in 2019, when most other countries were seeing a decline or similar numbers 
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to previous years. Data on dengue cases is more complete than for Zika and chikungunya thus 
trends seen for dengue cases are more likely to be accurate. 
Figure 3 shows the dengue and severe dengue cases for the select Barbados and the ECC 
countries reporting severe dengue cases for 2014 - 2019. Barbados and Dominica have reported 
severe dengue cases during the 2014 - 2019 period. Although, zero cases of severe dengue have 
been reported from all Barbados and ECC countries since 2016. The maximum reported number 
of severe dengue cases was in Barbados in 2014 (2 cases). There was less than 1% of dengue cases 
developing severe dengue.  
Figure 4 shows the reported chikungunya cases in Barbados and the ECC excluding FD for 
2014 - 2019. Epi week 15 was the last reported week for 2019. There were no reported 
chikungunya deaths and very few imported cases from the countries that did report data. The 
imported cases were reported in Anguilla (2 cases in 2014) and Barbados (8 cases in 2014). No 
country reported 2017 data regarding chikungunya cases. Saint Kitts and Nevis (2 cases) and Saint 
Lucia (2 cases) were the only reporting countries in 2018.  In 2019, Barbados (27 cases) and Saint 
Lucia (0 cases) were the only reporting countries. Regarding Barbados not reporting CHIKV cases 
in 2018 and reporting 27 cases in 2019 does not indicate a trend showing VC operations failed for 
the year.  Moreover, with the Zika outbreak in 2015 - 2016, it is possible that the reports for 
chikungunya decreased due to the greater concern for the higher morbidity attributed to Zika and 
thus a re-focus of limited resources. 
Of the countries that reported, there were no imported cases or deaths attributed to Zika in 
2015 - 2019 in Barbados and the ECC. Figure 5 shows the reported Zika cases in Barbados and 
the ECC excluding FD for 2015 - 2019. Epi week 12 was the last reported week for 2019 with zero 
cases reported for the few countries submitting data. In 2016, every country reported Zika cases. 
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Again, it appears there were zero cases reported for numerous countries in 2017 - 2019, yet many 
countries did not report any data. Even with a spike in Zika cases in 2016 followed by the lack of 
cases from 2017 onwards, this does not necessarily indicate VC operations are truly successful. 
Interestingly, in 2016 with the Zika outbreak in the Caribbean, there was also some spikes in cases 
reported for chikungunya and dengue. 
The CDC (2018) mentioned, “… ‘epidemiologic silence’ does not mean absence of risk, 
travelers should not go into endemic areas without taking protective measures.” The lack of 
chikungunya and Zika cases reported by numerous countries makes it appear as if there were zero 
cases, this is likely not the case as the lack of a report does not equate to zero cases reported. 
Failure to report cases may be intentional as there is no requirement to submit data to PAHO. 
Countries may fear losing tourists if there is a perceived health threat, so by not reporting cases it 
artificially looks safer to visit the countries. Therefore for the PLISA data, there is concern that a 
lack of report does not mean the Ministries of Health in those countries are finding zero cases. 
Further, the lack of reports or reporting zero cases should not mean for those living in those 
countries that it is safe to stop all VC efforts nor is it indicative of vector control program 
effectiveness. 
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Figure 2 The number of all dengue cases in Barbados and ECC excluding the French Department of the 
Americas (Guadeloupe, French Guiana, and Martinique) for the years reported, 2014 - 2019.  
Data source: PAHO’s PLISA 
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Figure 3 The number of all dengue cases and severe dengue cases in Barbados and ECC excluding the French 
Department of the Americas (Guadeloupe, French Guiana, and Martinique) for the countries reporting and 
for the years reported, 2014 - 2019.  
Data source: PAHO’s PLISA 
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Figure 4 The number of chikungunya cases in Barbados and ECC excluding the French Department of the 
Americas (Guadeloupe, French Guiana, and Martinique) for the years reported, 2014 - 2019.  
Data source: PAHO’s PLISA and Chikungunya: Data, Maps, and statistics 
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Figure 5 The number of Zika cases in Barbados and ECC excluding the French Department of the Americas 
(Guadeloupe, French Guiana, and Martinique) for the years reported, 2015 - 2019. 
Data source: PAHO’s PLISA 
 34 
3.0 PAHO and WHO’s Strategies for Prevention and Control of Arboviruses 
Strategies for mosquito control have changed throughout the last century. As previously 
mentioned, there was a mostly successful mosquito elimination campaign, primarily using 
insecticides, in the early to mid 20th century. This fell apart as it became more successful mostly 
due to lack of continued political will and financial resources, mosquito resistance to insecticides 
used, increased international travel, and insufficient environmental sanitation facilitating the re-
introduction and spread of A. aegypti. Further, the lack of a strong surveillance system hid the 
emergence of A. albopictus and thus the ability to institute timely control measures. (Brathwaite, 
et al., 2012; Webb, 2016) Moreover, any new strategies must learn from and adapt previous 
elimination efforts while incorporating new technology and engaging the public as populations are 
larger combined with a larger volume of global trade (including used tires) than that of the mid-
20th century contribute to further increased susceptible population and global spread. (Paupy, et 
al., 2009; Webb, 2016) In 2001, most dengue control programs were vertical, requiring a strong 
sustained political will with economic commitment and typically with the focus being on using 
adulticides and eliminated breeding sites. (Paupy, et al., 2009) PAHO aimed to promote a new 
strategic framework to have some continuity in programs developed by each country while keeping 
their specific needs in mind and allowing for their specific social, economic, political, historical, 
and cultural contexts. Included in the framework was to strengthen dengue prevention and control 
in national programs through improved surveillance, community participation, and social 
communication and advocacy. The developed programs from this framework were to rely on 
concomitant actions from intersectoral partnerships for sustainable environmental planning, urban 
planning, improved access to water and sanitation, and health education. To accomplish this by 
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using a diagonal approach with the local government acting as an active leader of the programs 
with individual households, communities, non-governmental organizations (NGOs), educational 
sectors, environmental sectors, private industry, and the healthcare sector participating. The local 
government would implement health education, legislation, solid waste disposal, and water supply 
and disposal (so homes and businesses can eliminate the need for rainwater collection). 
(Brathwaite, et al., 2012; PAHO, 2001) Using a diagonal approach ensures VC programs optimize 
their limited financial and human resources. (PAHO, 2016d) Additionally, the desire was to move 
into actions for prevention as opposed to reactionary due to an outbreak. Programs that wait for an 
outbreak before taking action can soon find each outbreak escalating due to the increased vector 
prevalence and increased dengue serotype circulation. Moreover, to save adulticides for during 
outbreaks due to its ephemeral effect. To accomplish this strategy, PAHO developed a 
standardized dengue data reporting and dissemination procedure, previously mentioned in the 
Epidemiology Data section. In the strategy some preventative methods mentioned are using 
larvicides and source reduction (the most effective method for reducing mosquito density) and that 
both require maintenance and can be time-consuming. (PAHO, 2001) Source reduction is 
something that everyone in the community can participate in, schools, churches, local industries, 
residents, and so on. (Paupy, et al., 2009; PAHO, 2001, 2016a) The activities taken for VC should 
be nation-wide as mosquitoes and social determinants of health do not adhere to borders, thus the 
need for collaboration among different sectors and effective communication between neighboring 
countries. 
The 2001 PAHO framework along with the increasing dengue incidence, became the 
backbone for future strategic framework. This includes the 2003’s Integrated Management 
Strategy for Dengue Prevention and Control (IMS-Dengue) that focused recommendations on 
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intersectoral participation and action for integrated vector management (IVM), epidemiology, 
entomology, healthcare, laboratories, the environment, and social communication with clear 
definitions and responsibilities within the scope of expertise for strengthening national programs. 
Also included was for countries to develop strategies for responding to outbreaks. (Brathwaite, et 
al., 2012; PAHO, n.d. g)  
Integrated vector management is an important part of vector control. IVM involves multi-
sectoral/intersectoral approach using multiple efficacious, ecologically sound, and sustainable 
resources for vector control as history has proven one method is not sufficient for mosquito control 
due to the selective pressures it creates. (ECDC, 2016a; WHO, n.d. b) Included in IVM is the use 
of advocacy, social mobilization, intersectoral collaboration, use of chemical and biological VC 
methods for the adult and immature or aquatic (egg, larva, and pupae) stages, operational 
entomological and epidemiological surveillance, and training and capacity building in the 
community and in the various levels of government. (WHO, n.d. b) It is easy to see that since 2001, 
IVM has been integral in all the framework PAHO has introduced. 
Soon after the chikungunya outbreak and during the Zika outbreak in the Americas, and 
further building on previous strategic frameworks developed (mentioned above), PAHO 
developed the Strategy for Arboviral Disease Prevention and Control (IMS-Arbovirus) in 2016 as 
each arbovirus cannot be viewed as an independent problem. Again the focus for the strategy’s 
framework was on intersectoral collaboration on comprehensive surveillance, laboratory 
diagnosis, patient care, and IVM emphasizing social participation. Accomplished through 
environmental management, surveillance, encouraging political will and financial commitment, 
strengthening the health sector capacity in differential diagnosis (along with laboratories), 
arboviral disease management, and communication with the community. Importantly, there was 
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the inclusion of ensuring the most vulnerable in the population are protected, involving and 
empowering the community to actively participate in VC, and using the WHO’s vector control 
advisory group to help pilot testing new VC tools, e.g. sterilized male mosquitoes, Wolbachia 
infected mosquitoes, and new tools as developed. Moreover, to strengthen and ensure evidence 
based decisions by including entomology and epidemiology data in program evaluations. (PAHO, 
2016d) 
Source reduction relies on a behavior change and community engagement, in order to be 
successful and sustainable it is important to know the communities, health care providers, and 
politician’s knowledge, attitudes, and current practices regarding mosquito control and prevention, 
preferred communication sources, and the current available government services. (PAHO, 2001) 
Knowing potential barriers and facilitators in each target area in a country will allow for a tailored 
approach to meet the needs of the community. Another helpful tool developed from PAHO’s 2001 
strategy, is the WHO’s communication for behavioral impact strategy (COMBI) a method for 
approaching behavior changes with social mobilization and communication. (PAHO, 2001, 2016d; 
WHO, 2012) 
Through all of these frameworks developed, PAHO acts as the technical advisor and 
support for countries regarding community engagement, capacity building for the health sector, 
surveillance, and social mobilization. Although PAHO cannot enforce any strategies or plans, that 
is entirely at the discretion of each sovereign nation. (PAHO, 2001, 2016d) In 2018, this was 
further laid out in PAHO’s Plan of Action on Entomology and Vector Control 2018-2023 plan of 
action document. The document proposed a plan to accelerate the control and elimination of 
vector-borne diseases through five strategic lines of action that would strengthen IVM and human 
capacity. The second line of action specifically involves engagement and mobilization of regional 
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and local governments and communities for sustained vector control and prevention. In this action 
is for countries to develop effective community engagement, mobilization, and communication 
while paying attention to social dynamics. (PAHO, 2018b) This is where Mosquito Awareness 
Week fits. By providing a week for Ministries of Health to focus on the community engagement 
aspect of IVM through training, education, and capacity building. Aimed to accomplish behavior 
change for the community, healthcare providers, other ministries, and the private sector. Over time 
and with sustained VC efforts, the goal is for the number of arboviral disease cases and outbreaks 
to decrease due to the entomological decrease in Aedes mosquitoes. 
3.1 Mosquito Awareness Week 
Caribbean Mosquito Awareness Week (MAW) is a collaborative effort between the 
Caribbean Public Health Agency (CARPHA), Caribbean Community (CARICOM), and PAHO. 
The goal is to strengthen existing regional initiatives and engage the public to take action and 
remove mosquito breeding grounds.  According to CARPHA, the initiative aims to “bring the 
region together to protect communities against diseases such as dengue, chikungunya, Zika spread 
by the Aedes aegypti mosquito, and malaria spread by the Anopheles mosquito.” (CARPHA, n.d.) 
The yearly initiative was started in 2016 by CARPHA due to the concurrent Zika outbreak 
in the Caribbean. The first MAW had 13 Caribbean countries and territories participating and 
focused on Zika and the associated risks for pregnant women. Due to its success, PAHO expanded 
the program to the entire Americas region. (CARICOM, 2016; PAHO, 2016b, 2018a) All future 
references to MAW are focused to the Caribbean MAW program and activities. MAW 2017 
primarily focused on messaging through increasing health care workers responsibilities for 
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disseminating information to their patients regarding personal protective measures and eliminating 
mosquito breeding sites. The secondary focus was on action by strengthening household and 
community participation in vector control. (CARPHA, 2017; PAHO, n.d. a) There was no 
evaluation of 2017’s Mosquito Awareness Week’s activities for participating Caribbean countries 
and territories. MAW 2018 efforts focused messages reaching the male and female heads of 
households to eliminate mosquito breeding sites around their homes. (PAHO, n.d. b) From the 
2018 report, only six countries and territories reported participation in MAW activities. This led 
to MAW 2019’s focus of getting VC efforts onto each Caribbean countries MoH’s agenda so as 
to have continued education and mosquito eradication efforts. 
The theme, “Small Bite, Big Treat” and the slogan, “Fight the Bite, Destroy Mosquito 
Breeding Sites” was the same theme and slogan as in previous years. (PAHO, 2019) Mosquito 
Awareness Week’s intention were to educate children over 12 years of age and the heads of 
households regarding diseases spread by mosquitoes, how to protect from getting bitten, and 
identifying and removing mosquito breeding sites around the house. (CARPHA, 2019; PAHO, 
n.d. c, 2019) Secondary, was targeting healthcare workers, community leaders, and civil society 
in disease prevention and environmental protection. (PAHO, 2019) By educating and empowering 
people, together the Caribbean can fight mosquito borne diseases. (CARPHA, 2019) Caribbean 
Mosquito Awareness Week 2019 occurred 6-12 May 2019. (PAHO, n.d.c) 
According to the MAW 2019 concept note, PAHO gave countries the proposal on MAW 
objectives, some guidelines on the communication campaign, intended audiences, as well as tips 
on planning, implementation, and evaluation of MAW activities. To also help countries with 
planning activities, a list of suggested events for the national and community level were included. 
But ultimately the MAW objectives, the communication and social mobilization strategies, and 
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indicators of success were left to the countries to determine in order to better accommodate the 
specific needs of each country to facilitate better integration of activities. The concept note is to 
serve more as a call-to-action. MAW 2019’s audience included the MoH and other ministries, 
other authorities including community leaders, the private sector, primary health care workers, 
vector control officers, families, and civil society organizations. Ultimately, PAHO wanted 
entomology and VC teams working with the communication and health promotion teams. The 
main objective for MAW 2019 was to increase political will for increasing vector control to 
promote sustained behavioral change, regarding eliminating mosquito breeding grounds, in 
different populations. The specific objectives included: 
● For decision-makers to increase commitment to implementing policies to improve the 
conditions that will aid in the prevention and control of mosquitoes, 
● For all countries in the region to participate and include MAW annually in official 
agendas, as well as to promote with regional media campaigns, 
● Promote information dissemination to the community and tourists through the tourism 
sector and medical professionals 
● Promoting social mobilization and participation of the community to eliminate mosquito 
breeding sites 
○ Facilitate intersectoral coordination of activities for vector control 
● Support the tourism sector to provide personal protection supplies against mosquitos to 
tourist  
● Raise awareness among medical professionals as to their roles in information 
dissemination regarding patients’ personal protection methods and mosquito breeding site 
elimination 
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4.0 Methodology 
Anguilla, Antigua and Barbuda, the British Virgin Islands, Dominica, Saint Lucia, and 
Saint Vincent and the Grenadines were the countries in PAHO’s Barbados and ECC region that 
participated in Caribbean Mosquito Awareness Week 2019. These countries submitted photos, 
videos, and/or a report of the completed activities to the Climate Change and Environmental 
Determinants of Health Advisor for the Barbados and the ECC PAHO office. Additional sources 
included social media posts and newspaper articles reporting on the event. Activities were 
compiled, limitations assessed, and recommendations given for future Mosquito Awareness Week 
activities.   
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5.0 Mosquito Awareness Week 2019 Evaluation and Evidence 
Table 1 List of activities performed by ECC participating in 2019’s Caribbean Mosquito Awareness Week. 
Country Department Location Activities Dates Source 
 
Anguilla 
 
Department 
of Health 
and 
Protection, 
Health 
Authority 
of 
Anguilla, 
NHPD 
Kool FM, 
Radio 
Anguilla, 
Upbeat and 
Klass FM 
• Using radio for 
press release (13th), 
mosquito jingle & 
text messages (13-
17th) 
13-17 
May 
 
Submitted 
schedule of 
planned events 
3 schools School lecture at:  
• St. Mary’s pre-
school (13th) 
• Orealia Kelly 
Primary School 
(14th) 
• Vivien Vanterpool 
Primary (15th) 
13-15 
May 
Not provided • Business search & 
destroy day 
14 
May 
General Post 
Office, The 
Valley 
• Community 
outreach awareness 
program 
15 
May 
Scotiabank, 
The Valley 
Community Outreach 
Awareness program: 
• Advice and 
instructions for 
controlling the 
spread of 
mosquitoes and 
rodents by 
providing 
instructions on traps 
and poisons to use 
• Displayed Gravid 
Trap (for Culex) 
and GAT-Trap (for 
Aedes) and 
explained how they 
17 
May 
The Anguillian 
Newspaper-gave 
contact info for 
the Department 
at the event in 
case the public 
has questions or 
needs assistance 
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Country Department Location Activities Dates Source 
work 
• Rat poison 
education on 
toxicity and 
personal protective 
equipment 
• Personnel willing to 
assist with 
deterrents and gave 
out contact 
information 
 
Antigua 
and 
Barbuda 
 
Ministry of 
Health and 
The 
Environ-
ment 
“Join the 
fight and 
lessen the 
bite” 
 
Parade 
through St 
John 
Health, Wellness and 
the Environment 
Minister talked to 
Central Board of 
Health Workers: 
• His message: keep 
working hard (as 
part of parade) and 
that the diseases 
trying to prevent are 
serious and 
prevention makes 
the doctors work to 
treat less futile 
• He encouraged 
everyone that 
source reduction is 
possible for all to 
accomplish.  
• Mosquito jingle 
• Parade (NGOs and 
Central Board of 
Health Workers) to 
hand out placards, 
flyers, and banners 
for the anti-
mosquito message 
 
8 July 
 
Ministry of 
Health and The 
Environ-ment 
Facebook posts 
 
Judgement 
Square on 
Market Street 
Grand exhibition: 
• Posters of how to 
prevent & clear 
breeding sites, the 
9 July 
Table 1 Continued 
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Country Department Location Activities Dates Source 
mosquito life cycle, 
removing stagnant 
water & covering 
drums 
• Banner from Red 
Cross and USAID 
on protecting and 
preventing Zika 
methods 
• Tent with info and 
BTI and other 
larvicides/ 
adulticides (and 
instructions for use) 
and mosquito larvae 
to see, diorama of 
how to protect yard 
via source reduction 
St. John • Pamphlet (Zika 
prevention for 
children, elderly, 
and general info), 
flyer, leaflet 
handout to nearby 
pedestrians and 
drivers 
Fort James 
beach in the 
morning and 
Runaway 
Beach in the 
afternoon 
Beach clean-up: 
• Video encouraging 
public to carry their 
trash out 
• Video and photos of 
Central Board of 
Health Workers 
cleaning Beaches as 
part of grand litter 
picking exercise (50 
workers and 60 
bags of trash) 
10 July 
Dredgers 
Play-field 
• Video and photos of 
Central Board of 
Health staff 
11 July 
Table 1 Continued 
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Country Department Location Activities Dates Source 
received certificate 
of appreciation (for 
length of service of 
20 to 37 years) and 
gifts during MAW 
Sports Day 
• Posted PAHO’s 
YouTube video 
Rain Barrels 
(Together) and The 
Ross Hill Swat Club  
• Videos from the 
MAW Sports Day 
(open to the public 
and for the vector 
control workers to 
enjoy as well) 
Not provided • Leaflet and flyer 
distribution at all 
major supermarkets 
on the island 
(mentioned, but no 
photos/videos 
posted) 
12 July 
 
British 
Virgin 
Islands 
 
Ministry of 
Health and 
Social 
Develop- 
ment, 
Environ- 
mental 
Health 
Division 
Primary 
Schools on 
Tortola 
island 
(grades 2-4) 
Francis 
Lettsome 
Primary 
School 
grounds 
80 students 
participated 
• Describe diseases 
transmitted by 
Aedes aegypti 
• Teaching the 
mosquito life cycle 
& observe larvae 
and pupae 
• “Mosquito Breeding 
Sites Treasure 
Hunt” activity  
6-12 
May 
Submitted video 
& report  
Ivan Dawson 
Primary 
School 
grounds 
48 students 
participated 
• Discuss importance 
of destroying 
mosquito breeding 
Table 1 Continued 
 46 
Country Department Location Activities Dates Source 
sites 
• Student & teachers 
discussion on 
mosquitoes  
• ”Mosquito Trivia” 
winners got a 
certificate 
Joyce 
Samuel 
Primary 
School 
grounds 
52 students 
participated 
• Discussing 
mosquitoes’ 
potential breeding 
sites 
• Talking to students 
& teachers (students 
seeing larvae & 
pupae) 
Mosquito 
Exhibition in 
Road Town 
• Explaining 
mosquito life cycle 
to public 
• Handing out 
pamphlets 
• Model house 
showing potential 
breeding sites (and 
life cycle) 
• Talking to public 
• Have a fogger and 
insecticides along 
with pamphlets and 
mosquito 
larvae/pupae for 
people to see 
12 
May 
 
Dominica 
 
Environ- 
mental 
Health 
Department 
Castle Bruce 
Platform 
(Playing 
field), Weirs 
Flat in 
Marigot, 
Bath Estate, 
& Anse de 
• Mosquito Drum 
proofing  
(Supported by National 
Pest & Termite Control 
Ltd. Dominica Red 
Cross, and the Health 
Promotion Unit) 
 
6-10 
May 
Submitted report 
and photos 
Table 1 Continued 
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Country Department Location Activities Dates Source 
Mai Flat 
Castle Bruce 
Primary 
School 
• Tire painting 
Schools in 
their usual 
classrooms 
in Roseau 
Health 
District, 
Wesley 
Health 
District, 
Portsmouth 
Health 
District, & 
St. Joseph 
Health 
District 
• Mosquito Education 
Awareness (health 
education sessions 
at): 
• Awareness on: 
mosquito life cycle, 
breeding sites, 
diseases, and 
prevention tips, also 
observe larvae and 
pupae 
• Use of PAHO’s 
SWAT Workbook 
• Certification of 
participation 
awarded at Salybia 
Primary School 
Convent 
High School 
grounds 
• Mural painting 
depicting mosquito 
breeding sites by 
the High School’s 
4-H club 
(Sponsored by the 
Dominica Red Cross) 
Kingshill Mosquito Drive: 
• Vector control 
surveillance in the 
community by the 
Environmental 
Health officers and 
Vector Control 
Officers 
• Education material 
distributed to 
households 
Table 1 Continued 
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Country Department Location Activities Dates Source 
 Open Air Meeting: 
• Education session 
on mosquito control 
and waste 
management 
(Soufriere 
Village Council 
collaborated) 
 
St. Lucia 
Department 
of Health 
and 
Wellness, 
Environ- 
mental 
Health 
Division; 
Training 
also by 
Bureau of 
Health 
Education, 
Saint Lucia 
Solid 
Waste 
Manage-
ment 
Authority, 
Substance 
Abuse 
Secretariat 
Anse La 
Raye 
Constituency 
Council 
VC training, 15 
participants trained 
• Trained on how to 
analyze collected 
data and plan 
appropriate 
interventions 
• Drafted sustainable 
VC plan, agreed by 
both the council and 
Environmental 
health division 
2-5 
July 
Submitted report 
on July 19, 2019 
Castries 
Southeast 
Constituency 
Council 
• VC training 23- 26 
July 
Vieux Fort & 
Dennery 
Constituency 
Councils 
• Last 2 VC trainings 
(no further data 
available) 
August 
2019 
 
St. Vincent 
and 
Grenadines 
 
Ministry of 
Health 
Wellness & 
the 
Environ-
ment 
Various 
primary 
schools in 
their usual 
classrooms 
Health education 
sessions on Leeward 
coast, St. Vincent: 
Spring Village 
Methodist, West Wood 
Methodist, Troumaca 
Primary, Fitz Hughes 
Primary, and 
Chateaubelair Primary 
School 
• Lectures (with 
information 
6 May Submitted video 
and report 
Table 1 Continued 
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Country Department Location Activities Dates Source 
handouts), mosquito 
identification 
(microscopes) 
In students’ 
usual 
classrooms 
 
Health education 
session at Paget Farm 
Primary School in 
Bequia: 
• Lectures (with 
information 
handouts), mosquito 
identification 
(microscopes) 
 
7 May 
Done in 
various 
communities 
across St. 
Vincent 
• Whistle stop on 
Leeward Coast, St. 
Vincent starting at 
Layou and 
Barrouallie 
In students’ 
usual 
classrooms 
Health education 
session on Windward 
coast, St. Vincent 
(Georgetown Primary, 
Dickson Primary, 
Langley Park Primary, 
Tourama Primary, and 
Sandy Bay Primary 
school) 
• Lectures (with 
information 
handouts), mosquito 
identification 
(microscopes) 
 
8 May 
Union Island • Health Fair at the 
Captain Hugh, 
Mulzac Square in 
Clifton 
Done in 
various 
communities 
• Whistle stop 
starting at Owia 
9 May 
Table 1 Continued 
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Country Department Location Activities Dates Source 
across St. 
Vincent 
 
Port 
Elizabeth 
• Health fair 
Done in 
various 
communities 
across St. 
Vincent 
• Whistle stop in 
Georgetown area 
10 
May 
 
From the submitted documents, Saint Lucia was the only country that developed several 
specific objectives: to reduce the vector population by 25% and to train 70 constituency council 
members in the targeted communities by September 2019. The British Virgin Islands, Dominica, 
and Saint Lucia listed objectives in their report congruent with the concept note. The 
communication slogans and themes were the same on all the participating islands. The British 
Virgin Islands added to the MAW slogan “Protect yourself, reduce mosquito breeding sites, and 
keep mosquitoes out.” Saint Vincent and the Grenadines ended their submitted video with “Our 
Health is a Shared Responsibility.” Lastly, Antigua and Barbuda used “Small bite, big threat. Join 
the Mosquito Fight and Lessen the Bite.” 
 All activities submitted by the participating countries are included in Table 1. The use of 
audio messages was not as pronounced in the reports as in previous years’ activities. Yet, as in 
2016, Anguilla used radio messages and text messages to reach the entire island. This year Antigua 
and Barbuda used PAHO’s Mosquito jingle during their activities and parade as well as posted 
PAHO’s YouTube videos Rain Barrels (Together) and The Ross Hill Swat Club on the Ministry 
of Health and the Environment’s Facebook page.  
Table 1 Continued 
 51 
 Anguilla, the British Virgin Islands (BVI), Dominica, and Saint Vincent and the 
Grenadines had children focused health education sessions located in schools. BVI mentioned they 
focused on school aged children due to previous experiences showing school aged children retain 
the information and pass it to other household members. Anguilla only mentioned they visited 
three schools during MAW 2019. BVI (visited three primary schools), Dominica (visited four 
schools), and Saint Vincent and the Grenadines (visited ten schools) elaborated more as to the 
curriculum of their health education sessions. Common was education on identifying Aedes 
aegypti mosquitoes, the mosquito life cycle, diseases transmitted by mosquitoes, how to identify 
common breeding grounds and the importance of cleaning your surroundings, and how to protect 
yourself from being bitten. Additionally, students were able to observe live mosquito larvae and 
pupae. Health education sessions were taught by Environmental Health Officers (EHO) and/or 
Vector Control Officers (VCO) either in the student’s classroom or on the school grounds.   
Specific to BVI’s health education sessions the Environmental Health Division staff and 
VCOs explained their roles and responsibilities regarding mosquito control. As part of the session, 
students were encouraged to share prior knowledge on mosquitoes. Included in the session was a 
model house with some commonly found items to display mosquito breeding sites. Prior to the 
health education sessions, the VCO and Environmental Health Division staff went around Francis 
Lettsome school grounds to stage, and in some cases use existing, mosquito breeding containers 
to be used in a “Mosquito Breeding Sites Treasure Hunt.” Students organized into groups with an 
Officer as team leader. The group who found the most breeding sites received a certificate of 
achievement for outstanding vector control activities. The other schools visited on BVI did not do 
a treasure hunt due to the weather and instead participated in group trivia on what was discussed 
during the health education sessions. The winning group also received a certificate of achievement. 
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BVI deemed Mosquito Awareness Week 2019’s health education sessions in schools a success 
that will continue in future Mosquito Awareness Week programs. 
Dominica kept the same focus as in 2016: health education in schools and mosquito 
proofing barrels (mentioned below). Dominica’s Mosquito Education Awareness was led by EHOs 
and certificates of participation were handed out to students at Salybia Primary School and Castle 
Bruce Health District. Also part of the mobilization efforts in Dominica included painting a mural 
depicting mosquito breeding sites, completed by the Convent High School 4-H club and sponsored 
by the Dominica Red Cross. Additionally, Dominica’s Castle Bruce Primary School painted some 
used car tires. The end goal of the painted tires was not described in the report or alluded to in the 
photos. It is possible they were used for gardening efforts as has been seen on Caribbean islands. 
From the video Saint Vincent and the Grenadines submitted, it appeared as if while doing the 
health education sessions on the school grounds the Officers also talked to community members 
who approached them. 
 Community education efforts appeared to be another common activity among the 
participating countries. Antigua and Barbuda’s community education included a parade of NGOs 
and the Central Board of Health Workers staff who all handed out flyers to pedestrians. The parade 
was attended by the Health, Wellness and the Environment Minister who encouraged workers to 
continue source reduction to prevent diseases. They also handed out flyers at major supermarkets 
on the island. Additionally, Antigua and Barbuda hosted a Grand Exhibition with posters on how 
to prevent and clear breeding sites, the mosquito life cycle, and to remove stagnant water and cover 
drums/barrels. Part of the Grand Exhibition included information on larvicides and adulticides, 
observable mosquito larvae, and a diorama of how to do source reduction to protect your home. 
To celebrate their staff, they initiated MAW Sports Day where Central Board of Health Staff and 
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the community could play sports together. During the MAW Sports Day, the Central Board of 
Health Staff who worked 20 to 37 years were given a Certificate of Appreciation.  
Anguilla’s Community Outreach Awareness program involved displayed traps and poisons 
with advice and instructions for controlling the spread of mosquitoes and rodents. BVI hosted an 
exhibition located in a high traffic place and used a tent sponsored by the BVI Digicel branch. In 
addition to the same information presented at Antigua and Barbuda’s exhibition, BVI presented 
insecticides, fogging machines, screens, repellent, observable larvae and pupae, and the same 
model house as used in the school’s Health Education Session. BVI mentioned they handed out 
over 300 educational brochures during the exhibition and reported community members were 
impressed and approved the efforts taken by the VCOs in preventing mosquitoes. Dominica also 
hosted an education session focused on mosquito control and waste management with the 
collaboration of the Soufriere Village Council. Lastly, Saint Vincent and the Grenadines hosted a 
health fair on Union Island to hand out information, with no specifics mentioned. 
 Dominica’s other focus, mosquito proofing drums, occurred in Bath Estate (13 drums), 
Marigot (30 drums), Anse de Mai (31 drums), and Castle Bruce (20 drums) with a total of 94 
mosquito proofed drums. The event was supported by National Pest & Termite Control Ltd., 
Dominica Red Cross, and the Health Promotion Unit. Additionally, the Dominica Red Cross 
donated the material to mosquito proof 20 drums in Bath Estate. From the pictures submitted, it 
appears as if Dominica had about 5 to 10 individuals attend each mosquito proofing drum session. 
 Saint Lucia focused entirely on capacity building through education in four high risk 
communities to address the high incidence of vector-borne diseases and waste management issues. 
Only one community’s Constituency Council, Anse Le Raye (15 participants), had completed the 
training. The training involved 1 to 3 days of classes covering nine courses: Introduction to Vector 
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Control, Mosquito Biology and Control, Vector Borne Diseases 1 (Mosquito Borne Disease), 
Rodent Biology and Control, Vector Borne Diseases 2 (Rodent Borne Disease, Leptospirosis), 
Integrated Vector Management, Use of Personal Protective Equipment, Environmental Factors 
Contributing to Vector Borne Disease, and Effective Communication and Substance Abuse. On 
training day 4 participants walked through the community to inspect for mosquito and rodent 
control opportunities. Additionally, the participants were trained to analyze data and plan an 
appropriate intervention as well as to draft a sustainable VC plan to be agreed by both the Council 
and the Environmental Health Division. The other targeted communities were scheduled to begin 
training at the end of July 2019 and in August 2019. Further reports and information was not 
available as such it is not currently possible to determine if Saint Lucia meet their specific 
objectives. 
 Another common activity included clean up and VC surveillance of communities. Anguilla 
hosted a Business Search and Destroy Day, again there was no report elaborating on the activities 
performed. Antigua and Barbuda’s Central Board of Health Workers gathered 60 bags of trash 
from two beaches. Dominica’s Mosquito Drive involved EHO and VCO inspecting 20 premises 
and handed out education materials. Lastly, Saint Vincent and the Grenadines did “Whistle Stops” 
which involved walking around neighborhoods on Saint Vincent handing out information packets. 
Additionally, an Officer dressed as a mosquito and visited several preschools and local shops.  
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6.0 Mosquito Awareness Week 2019 Discussion 
The inaugural Mosquito Awareness Week was established concurrent with the Zika 
outbreak in 2016. (CARICOM, 2016; PAHO, 2016b, 2018a) The Caribbean Mosquito Awareness 
Week is a collaborative effort between CARICOM, CARPHA, and PAHO to strengthen the 
existing regional vector control initiatives and engage the public to take action to remove mosquito 
breeding grounds. (CARPHA, n.d.) The main objective for MAW 2019 was to increase political 
will for increasing vector control to promote sustained behavioral change for eliminating mosquito 
breeding grounds in different populations. The countries that participated completed a variety of 
activities focused primarily on educational activities in the community and at schools. The British 
Virgin Islands mentioned they focus activities on school aged children due to previous experiences 
showing school aged children retain the information and pass it to other household members. By 
investing behavior change in children now, there is a greater change of sustained behavior change. 
The British Virgin Islands are the only country that included country specific 
recommendations, based on 2018 and 2019’s activities, for future BVI MAWs. They recommend 
to plan for February instead of April and to include more islands such as Anegada, Virgin Gorda 
(including partnering with their BugOut initiative), and Jost Van Dyke. For all the remaining 
recommendations BVI would like VCOs to be more involved as their roles and responsibilities 
takes them into the communities where the public interacts with them. Additionally, BVI wants to 
hand out repellents, mosquito screens, and larvicides in addition to pamphlets. Further, BVI would 
like to design more user friendly pamphlets that include an activity related to identifying mosquito 
breeding sites. BVI desires to contact more public and private schools and to develop new ways 
for more student engagement, e.g., drawing the mosquito life cycle, a slogan competition, a 
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mosquito awareness parade, and a short inter-school competition on vector control activities where 
the winners receive trophies from the Environmental Health Officers. Additionally, BVI would 
like to have a larger exhibition in collaboration with other governmental agencies and schools. The 
exhibition would have multiple stations displaying mosquito larvae, mosquito transmitted 
diseases, the three forms of control (chemical, biological, and physical), and other ideas as 
conceived. In addition to all the recommendations, BVI would like to reach more of their 
population. They propose using more media sources (TV, social media, and radio) as well as to 
have an interactive question and answer segment on the radio. While this is specifically mentioned 
by BVI, other countries could benefit from these recommendations as well. 
Regarding the British Virgin Islands desire to change the month of Mosquito Awareness 
Week activities, if MAW is on the Ministries of Health’s agenda in each country, then each country 
will have to approve a budget, human resource allocation, and planning for the activities and as 
such can plan the timeline to suit their specific needs. Additionally, as Aedes mosquitoes do not 
rely on rainfall for breeding sites and mosquitoes are present year round in the tropics, MAW 
activities can occur at any time of year in order to fit around other programs. (Klitting, et. al., 2018, 
Paupy, et. al., 2009; Simmons, 2012) PAHO setting the second week of May serves as a call to 
action and sets a goal of when to complete implement planned activities. This year’s MAW 
activities were completed by countries in May, June, and August (Table 1). In the 2016 Mosquito 
Awareness Week Report, it was noted that the original date was set for February yet being so early 
in the year it did not lend enough time for planning and implementation and thus future MAWs 
were set for April. 
Saint Lucia and Antigua and Barbuda’s activities appeared to focus less on education of 
school-aged children, which may be due to the Ministry of Education not allowing participation. 
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With the success other islands are having with this activity, if Saint Lucia and Antigua and Barbuda 
want to include school-aged children in their target population, it is recommended they contact 
Anguilla, BVI, Dominica, and Saint Vincent and the Grenadines regarding how they have 
successfully implemented visiting schools and collaborating with the Ministry of Education. 
Additionally, Dominica’s activities involved the collaboration with an NGO and a private 
business. Other countries may desire to contact Dominica to assist in methods for creating 
collaborations with other local organizations and businesses. 
Antigua and Barbuda’s Central Board of Health staff performed the beach clean-ups. It is 
recommended they encourage participation and education of the community on such activities. 
Doing so can build capacity and engage the community to keep their homes and communities free 
of mosquito breeding sites. There were some valid critical comments as well as supportive 
comments on Antigua and Barbuda’s Ministry of Health and the Environment’s MAW activities 
Facebook posts. The commenters essentially wanted more sustainability by enforcing fines, having 
public trash bins available, and to engage the community instead of just having the Ministry staff 
cleaning beaches. Without community capacity building and public trash bins it is possible the 
beaches and other community locations will be littered again. Placing public trash bins may require 
hiring more personnel to remove the trash. Another possibility is to promote a partnership with 
waste management services to donate the bins and help with trash removal or even enforcing a 
small littering fine that will cover installation and maintenance costs of garbage bins. 
Some recommendations from the 2016 and 2018 reports are still applicable for 2019 (again, 
there was no 2017 report).  In 2018 there was a recommendation to include Town Hall meetings 
so as to talk with the community and distribute education pamphlets. This too is a way to reach 
the community to discuss mosquito awareness and VC as well as to inform the needs of the 
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community and tailor the program.  As there are still some arboviral cases being reported in the 
Caribbean and with dengue’s endemo-epidemic cycles, it is important to continue Mosquito 
Awareness Week efforts towards behavior change and improving source reduction. 
MAW 2016’s recommendation to develop a strategy for collecting quantitative data on the 
impact and sustainability of the campaign is still valid. It is recommended to conduct a process 
and outcomes evaluation by determining indicators of success, finding or creating appropriate 
measurement tools, then collecting and evaluating data. Recommended measurement tools include 
key informant interviews of Vector Control officers and/or anyone implementing and operating 
the activities, interviews with non-participating countries, pre-post surveys of participants, 
systematic entomologic surveillance, and systematic epidemiologic surveillance. The goal would 
be to determine barriers and facilitators to program implementation and operation, determine 
correct knowledge retention, and determining program effectiveness. The evaluation report can be 
used to identify areas of improvement for future programs. 
 Regarding the media mentions, PAHO’s Assistant to the Country Program Specialist who 
are located in each country in the Barbados and ECC region were contacted to assist in providing 
local media mentions of MAW but none returned contact. This would be beneficial to assess the 
levels of media communications within countries and aid in understanding the programs reach. 
Limitations specific to Saint Lucia include low levels of literacy and education level, as 
determined by a pre/post-test. Additionally, they noticed more engagement when the lectures were 
in the Kweyol language. As Saint Lucia had three more Constituency Council’s to train, there was 
time to adjust the language and literacy level in the curriculum. Due to not receiving a follow up 
report, it is not known if changes were made and if so, were they more successful. As previously 
mentioned, Antigua and Barbuda’s Central Board of Health Staff performed the beach clean-up. 
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By not including the community in vector control operations it limits their capacity and the level 
of sustainability. Further, as there is no requirement on what to report to PAHO, there is no 
consistency on what information regarding the activities are reported. 
 It would be beneficial to discuss with non-participating countries to understand their 
reasons and barriers to MAW participation. Some potential reasons why countries have not 
participated in 2019’s Mosquito Awareness Week may be due to a focus on other diseases and 
health issues, the perception of low risk to arboviral diseases due to the overall trend of decreasing 
number of cases over the last year or two, or the time of the year for the activities. As already 
mentioned, by getting MAW on the MoHs agenda a budget and planning for the event is more 
likely. A budget can help cover the costs of printing pamphlets and posters, of which PAHO has 
the infographics listed online available for free. (PAHO, n.d. i) Additionally, MAW being on the 
agenda can alleviate insufficient human resources or competing priorities for human resource 
through resource allocation. Another potential barrier is the possibility of a lack of intersectoral 
collaboration at the higher governmental levels, such as needing the Ministry of Education’s 
involvement along with the MoH in order to plan and implement activities with schools. Along 
with the recommendation to include VCOs in more activities, it could be that those individuals 
may need more training on how to engage different target populations, such as children, parents, 
business owners, and those in the MoH or other ministries.  
Further, there were no activities aimed at the tourism industry and there may need to be 
more training of MoH and/or VCOs to engage tourists along with the need to collaborate with 
other sectors and other country’s governments. Additionally, as a region with a tourism-based 
economy this would be a large and population to target and as previously mentioned malaria 
followed by dengue is most diagnosed cause of fever in tourist returning from LMICs worldwide 
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indicating a population that would benefit from MAW activities. (WHO, 2019a; World Travel and 
Tourism Council, 2019) Moreover, tourist may be coming from arboviral non-endemic areas and 
thus may not know to perform important prevention methods, such as using mosquito repellent, to 
wear long sleeves and pants, or to use AC when available or stay in housing with screened 
windows. To reach this population, educational materials and mosquito repellent can be provided 
at airports, seaports, car rental locations, hotels, tour agencies, and at major tourist attractions and 
shops 
From all the MAW participating countries, there is no mention of a number of schools and 
participants in the activities and so there is no way to determine what percentage of the target 
population has been reached. This information can determined the level of coverage by the 
activities and where to concentrate efforts in the following years. Lastly, mentioned in the 
Mosquito Awareness Week 2019 concept note was to conduct a national entomological survey to 
assess the entomological risk of communities. By doing so, the MoH will be able to determine 
which areas need to be focused on for MAW activities and guide what activities are planned. This 
information along with a follow up survey can show the benefits of community engagement in VC 
and the data may be convincing for communities towards VC sustainability. 
6.1 Public Health Recommendations 
Arboviral diseases such as dengue, chikungunya, and Zika viruses all contribute to high 
morbidity in the Caribbean. (Brathwaite, et al., 2012; Paupy, et al., 2009; Webb, 2016) Everyone 
is at risk to arboviral disease to a varying degree dependent on the region’s rainfall, temperature, 
and environmental sanitation. (Paupy, et al., 2009; WHO, 2019a) Outbreaks from these diseases 
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also negatively affect economies and families. (Weaver, et al., 2016; WHO, 2019a; Yactayo, et 
al., 2016) Additionally, these viruses are transmitted by the same domiciliary mosquito with a 
preference for urban and peri-urban breeding sites. (Klitting, et al., 2018; Ngoagouni, et al., 2015; 
Paupy, et al., 2009; Powell, et al., 2013; PAHO, n.d. e; WHO, n.d. a) Since the beginning of the 
21st century, PAHO and the WHO have developed strategies and frameworks aimed at improving 
current mosquito prevention and control efforts. Fundamental to the strategy/frameworks is an 
escape from vertical programs and to include community participation as well as social 
communication and advocacy in an integrated vector management program. (PAHO, 2001)  
Due to the preferences of the Aedes mosquito, the arboviral disease prevalence and 
potential for outbreaks, and the lack of licensed vaccines available in the Caribbean (except in U.S. 
and European territories), the WHO, PAHO, and the CDC all recommend vector control for the 
protection of all populations. More specifically source reduction or environmental management 
methods is the most effective method with the biggest impact for reducing the number of mosquito 
breeding sites and thus mosquito population control. (CDC, 2017b; PAHO, 2016a; Paupy, et al., 
2009; Webb, 2016; WHO, n.d. a; ECDC, 2016a, 2016b) The domiciliary life of Aedes mosquitoes 
indicates the need for households to take the responsibility of vector control. Further, the whole 
community needs to participate in VC since one property not participating in source reduction and 
VC can sustain mosquitoes and thus disease transmission. (Paupy, et al., 2009; Weaver, et al., 
2016) Additionally, it is easy to imagine that if mosquitoes are always prevalent, that people could 
feel as if VC is impossible to accomplish. Conversely, motivation for mosquito control can also 
be due to the nuisance of mosquitoes and less due to the concern for acquiring and transmitting 
arboviral diseases. (Guzman, et al., 2010) Programs such as Mosquito Awareness Week, can be a 
source of education and capacity building by reaching out and engaging the community as well as 
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building intersectoral relationships to strengthen and sustain the VC efforts. Moreover, each 
Caribbean country will have to evaluate what is feasible, practical, and acceptable for their needs, 
while also understanding continued VC efforts are effective but require sustained messaging, even 
more so for the time-consuming efforts such as source reduction. 
VC includes, but is not limited to, larval source reduction or ‘cleanup’ campaigns via 
removing standing water sources around the house, schools, public spaces, cemeteries, and 
businesses weekly as well as removing unused containers and protecting used containers from 
becoming mosquito breeding sites. (Guzman, et al., 2010; Paupy, et al., 2009; CDC, 2017b; 
PAHO, 2016a; WHO, n.d. a) This includes rainwater barrels being protected with appropriate 
screens. PAHO has created a video, located on their website, on how to properly protect rainwater 
barrels from becoming mosquito breeding sites. (PAHO, n.d. b) Any water sources that cannot be 
removed or covered, such as water for livestock and companion animals, should be thoroughly 
and regularly scrubbed and to not solely rely on biological or chemical control mechanisms. This 
is because Aedes mosquito eggs attach to the container and once the eggs contact water they will 
hatch. (Powell, et al., 2013; PAHO, 2016a; ECDC, 2016b, WHO, 2019a)  
Other forms of vector control includes chemical controls such as larvicides and adulticides. 
(Guzman, et al., 2010) Adulticides are often used for space spraying or fogging. This method is 
not sustainable long them and to be most effective the insecticide needs to contact all surfaces. 
(PAHO, 2001) As such, space spraying typically is best left to use during outbreaks or when the 
adult mosquito populations are higher due to the failure of larval source reduction. (Paupy, et al., 
2009) Although exploring other options before using space spraying is best due to insecticide 
resistance in A. aegypti worldwide. A. albopictus is still susceptible to insecticides, but due to their 
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more diverse larval breeding sites it is more difficult to spray and clean all potential sources. 
(Hemingway, et al., 2009; Paupy, et al., 2009) 
Biological control methods typically work better for mosquito control and prevention than 
chemical methods and with less risk of mosquitoes developing resistance. Further, chemical 
controls need to be reapplied appropriately to properly work. (Guzman, et al., 2010; Paupy, et al., 
2009) Biological controls include, but not limited to, genetically modified mosquitoes, sterile 
mosquitoes, Wolbachia infected mosquitoes, and larvivorous fish and copepods. (Guzman, et al., 
2010; Paupy, et al., 2009; Simmons, et al., 2012; Ye, et al., 2015) The genetically modified 
mosquitoes are males that sterilize the wild-type female mosquito population. This method reduces 
the female’s egg output and therefore the size of the next generation. (Wise de Valdez, et al., 2011) 
Wolbachia is an obligate intercellular bacteria which is introduced into mosquitoes and has been 
shown to prevent dengue and chikungunya infections, thus preventing the spread of these disease 
to humans. Further, these mosquitoes can interact with wild-type mosquitoes and spread 
Wolbachia to the wild-type mosquitoes. (Moreira, et al., 2009; Ye, et al., 2015) The biological 
control methods still require effectiveness studies in different populations as well as addressing 
the concern of ethics and risk management. (Paupy, et al., 2009) There has been demonstrated 
effectiveness in insecticide treated curtains and water container covers in Mexico and Venezuela 
as well as using dominant lethal gene in mosquitoes, where the offspring with wild-type females 
result in death. (Kroeger, et al., 2006; Wise de Valdez, et al., 2011) Importantly, biological controls 
require facilities and expertise and more so for the ones that need to be frequently re-introduced 
such as the larvivorous fish, copepods, and sterile mosquitoes. (Guzman, et al., 2010) Therefore 
the importance of knowledge regarding disease epidemiology and entomological monitoring in 
order to properly allocate resources. (Simmons, et al., 2012) Moreover, with all the control 
 64 
methods, there is the need to educate the public on when and how to use the methods, how to 
determine which methods are best for each household, school, business, etc., as well as to leave 
larvivorous fish to do their role in larval control and to not eat or keep the fish as pets. 
Environmental management to reduce mosquito breeding sites can be performed at the 
individual, interpersonal, and community level in the social ecological framework such as source 
reduction or it can be at the institutional and policy level such as improvements to clean water and 
proper waste management services. Yet these improvements and changes require huge investments 
in infrastructure in order to increase the reach of safe water and solid waste disposal. This can be 
a concern if cost recovery mechanisms are put in place, such as metering water use which might 
encourage the return to collecting rainwater. (Guzman, et al., 2010) Thus it is important for 
intersectoral collaboration and for public health officials to work with ministries and civil society 
on infrastructure development. Even with improved water and sanitation it is still important to 
participate in other aspects of vector control and protection as behavior changes will aid in 
achieving long-term control of mosquitoes. (Guzman, et al., 2010) 
Health care systems can be stressed due to the unpredictability of outbreaks and developing 
severe dengue. (Simmons, et al., 2012) As such, it is important for individuals to understand signs 
and symptoms of arboviral infections and to seek prompt and proper medical attention. Ideally, 
primary care health professionals and to reserve hospitals for severe cases. The primary care health 
professionals should be trained on monitoring cases and the facilities should have the capacity for 
rapid ambulatory response as severe dengue can develop quickly. (Guzman, et al., 2010; Simmons, 
et al., 2012)  
Further assistance in rapid response would be improving early diagnosis and predicting the 
risk of developing severe dengue. (Simmons, et al., 2012) Thus the need for more specific and 
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sensitive diagnostic methods such as multiplex RT-PCR to detect virologic mono-infections and 
co-infections, PRNT or IgG ELISA to determine exposure serologically, as well as developing 
tests for other specific biomarkers of infection. (Ariën, et al., 2018; Guzman, et al., 2010; 
Kindhauser, et al., 2016; Waggoner, et al., 2016; WHO, 2019e) The tests should be commercially 
available and be able to be used at the point-of-care. (Guzman, et al., 2010; Sanofi, 2019) Proper 
training to run and interpret the results is necessary with any new equipment or method and 
commercially supplying companies offer troubleshooting assistance. Further, primary care 
facilities as well as hospitals should have the capacity to operate point-of-care diagnostic tests. 
Diagnostic tests are important for properly identifying the target population for Dengvaxia. (Ariën, 
et al., 2018; WHO, 2019e; Sanofi, 2019) More specifically, the WHO recommends viral diagnosis 
of acute dengue as once vaccination becomes more prevalent, serologic diagnosis can increase the 
false-positive rates. (WHO, 2019e) Sanofi is currently working on a point-of-care serological test 
that will be high sensitivity, so as to properly identify those with a previous dengue infection, and 
high specificity, to avoid vaccinating false positives and thus increase the risk of developing severe 
dengue. (Sanofi, 2019) The WHO also considers it acceptable to have quality hospital records of 
dengue cases to determine who is eligible for Dengvaxia vaccination. (WHO, 2019e) 
As mentioned above, there is a passive system already in place for the Americas region 
where Ministries of Health submit the numbers for suspected, confirmed, and imported cases to 
PAHO which is then reported back out via PLISA. This surveillance data is by country and by 
week. (PAHO, n.d. f) By having a common location for all the county data, there is a standardized 
case definition which enhances the ability for data sharing. Yet, as the PLISA data is aggregate, it 
makes it difficult to know where to prioritize finite resources within a country, thus higher 
resolution data is more desirable. Further, as mentioned above countries do not have incentive to 
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report cases for fear of losing tourists. To increase reliability of the data would mean increasing 
costs by making the system active surveillance or by having a regional requirement for accurate 
data submission to PAHO. A resource already available is CARPHA, a regional organization 
where Caribbean countries pool resources for the benefit of all their member states, offers capacity 
building in numerous areas including surveillance data and GIS (Geographic Information System). 
(CARPHA, n.d. a) PAHO is another already available resource, which acts in an advisory role and 
also provides some financial assistance.  
In order to understand where increased efforts are needed there needs to be a strong 
surveillance system in use. The improved diagnostics and a strong surveillance system are 
important due to the prevalence of numerous arboviral diseases with similar clinical symptoms in 
the region. (WHO, 2019e) Additionally, as these arboviral diseases have asymptomatic cases 
which leads to silent transmission and allows for accelerated disease transmission and 
geographical spread. Thus, necessitating a strong surveillance system that can aid in rapid 
identification and response to outbreaks. (Duong, et al., 2015; Nguyet, et al., 2013) Moreover, 
long-term, quality epidemiologic data is important for understanding if interventions are effective 
and more so as dengue has an endemo-epidemic cycle with higher cross-protection occurring after 
outbreaks. (Clapham, et al., 2017) For the current dengue vaccine, Dengvaxia, epidemiologic data 
can help determine which age range each country should target based on previous exposures so as 
to minimize risk of severe dengue cases. The surveillance systems also can aid in determining 
vaccination program impact, duration of immunological protection, and evaluating the vaccination 
schedule (as 3 doses can be a barrier for some individuals). (WHO, 2019e) Most important, 
regarding the dengue vaccine is the development of a safe, effective, and affordable vaccine that 
 67 
does not depend on known serostatus and produces life-long immunity to all four serotypes in one 
dose. 
All aspects of IVM, as described above, require good and transparent communication. 
Communication and data can aid in setting up intersectoral collaboration, advocating to ministries 
and the community the importance of VC, and for educational purposes. There needs to be a 
recognition of the significance of arboviral diseases leading to the commitment to IVM practices 
including the collaboration with other countries. Increased ministerial support includes using 
available tools, such as GIS and larvicides, as well as supporting research for other VC practices, 
improving organization of services, and making smart partnerships to accomplish IVM practices. 
(Guzman, et al., 2010) For Dengvaxia, it is important for citizens to know, from their ministers, 
the vaccination process, associated vaccination risks, and that the continuation of VC practices and 
prevention methods are still vital regardless of vaccination status. Further, individuals need to have 
confidence in their country’s national vaccination programs and accept the vaccine’s benefits and 
risks. If the risks are not accepted, the cases of severe dengue can erode the public’s acceptation 
of the dengue vaccine and other vaccines in the program. (WHO, 2019e) The WHO recommends, 
ministries find ways to cover the cost of the any arboviral vaccine and serologic tests prior to 
Dengvaxia inoculation and not at the expense of other public health programs, in order to decrease 
any potential inequities. (WHO, 2019e) Other forms of risk communication messaging can include 
printed materials and radio messages aimed at airports, seaports, and densely populated areas so 
as to reach tourists and locals. (Simmons, et al., 2012) As mentioned above, PAHO has 
communication materials on the Caribbean Mosquito Awareness Week website. These materials 
are free to use in print and on social media. Additionally it is important to know the target 
audience’s preferred method of communication to increase reach as well as knowledge gaps. This 
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information can come from KAP (knowledge, attitudes, and practices) studies. KAP studies can 
also inform on program participant’s retention of educational key points to aid in improving 
subsequent programs and educational materials.  
Specifically for Zika, there needs to be messaging, education, and access to family planning 
due to sexual transmission in addition to messaging and education for preventing mosquito 
transmission. (CDC, 2017c) It is important for health care providers in addition to VCO/EHOs to 
communicate the risks and prevention methods to women and their partners who are pregnant or 
trying to get pregnant. (WHO, 2018b) Thus, all pregnant women, women trying to get pregnant, 
and their partners should avoid areas known to have Zika or take the necessary steps to avoid being 
bitten by mosquitoes, including sleeping under mosquito nets when sleeping during the day. In 
addition, during pregnancy women should abstain from intercourse or using a condom. Those 
trying to conceive and have traveled to ZIKV endemic areas should wait the appropriate length of 
time for a presumptive infection to be cleared; women should wait two months and men, three 
months. (CDC, 2017c; WHO, 2018b, 2019f) Other general protective measures to prevent being 
bitten by mosquitoes and prevent disease transmission includes promoting the use of personal 
protective measures such as wearing long sleeves and pants, using mosquito repellent, and using 
screens on windows and doors or using AC if available. (Paupy, et al., 2009; CDC, 2017b; PAHO, 
n.d. e) 
Due to the regional history of failed interventions to remove or inhibit the spread of 
mosquitoes, even when vaccines are readily available, there will still be a great need for continued 
and vigilant vector management, timely diagnosis, and epidemiologic and entomologic 
surveillance to protect all populations by reducing morbidity and mortality. (PAHO, 2016d; Webb, 
2016) It is necessary to have ministerial support and an intersectoral approach with the appropriate 
 69 
ministries, health care professionals, and public health professionals collaborating on developing 
plans and resource allocation for handling concomitant arboviral outbreaks, seasonal illnesses, and 
natural disasters. Doing so would require quality, higher resolution surveillance data with proper 
educational materials and capacity building for the community. 
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Appendix A 2019 Caribbean Mosquito Awareness Week Media Mentions 
• https://theanguillian.com/2019/05/mosquito-awareness-week-vector-control-meets-the-
public/ (Anguilla) 
• https://www.facebook.com/investingforwellness/ (Antigua and Barbuda) 
• https://abstvradio.com/mosquito-awareness-week-a-success/ (Antigua and Barbuda) 
• https://www.nationnews.com/nationnews/news/239638/mosquito-awareness (Barbados) 
• https://m.facebook.com/story.php?story_fbid=10213881638130758&id=1102627985&sf
nsn=mo&s=100035315014849&w=n (BVI) 
• https://www.nationnews.com/nationnews/news/239710/carpha-fight-bite (CARPHA’s 
article in Barbados) 
• http://drealfmgrenada.com/index.php/2019/05/14/carpha-urges-the-region-to-deal-
seriously-to-eradicate-mosquitoes/ (same CARPHA article in Grenada) 
• https://www.dominicavibes.dm/news-257939/ (Dominica) 
• https://kairifm.com/dominica-observes-mosquito-awareness-week-2019/ (Dominica) 
• https://drive.google.com/file/d/1QKNqYCD1_n_6ATlLifSMbBVUMsSmGrAy/view 
(Saint Vincent and the Grenadines) 
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